1
|
Ye L, Greten S, Wegner F, Doll-Lee J, Krey L, Heine J, Gandor F, Vogel A, Berger L, Gruber D, Levin J, Katzdobler S, Peters O, Dashti E, Priller J, Spruth EJ, Kühn AA, Krause P, Spottke A, Schneider A, Beyle A, Kimmich O, Donix M, Haussmann R, Brandt M, Dinter E, Wiltfang J, Schott BH, Zerr I, Bähr M, Buerger K, Janowitz D, Perneczky R, Rauchmann BS, Weidinger E, Düzel E, Glanz W, Teipel S, Kilimann I, Wurster I, Brockmann K, Hoffmann DC, Klockgether T, Krause O, Heck J, Höglinger GU, Klietz M. The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis. J Neurol 2024; 271:2639-2648. [PMID: 38353748 PMCID: PMC11055732 DOI: 10.1007/s00415-024-12207-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Accepted: 01/16/2024] [Indexed: 04/28/2024]
Abstract
BACKGROUND Multiple system atrophy (MSA) is a complex and fatal neurodegenerative movement disorder. Understanding the comorbidities and drug therapy is crucial for MSA patients' safety and management. OBJECTIVES To investigate the pattern of comorbidities and aspects of drug therapy in MSA patients. METHODS Cross-sectional data of MSA patients according to Gilman et al. (2008) diagnostic criteria and control patients without neurodegenerative diseases (non-ND) were collected from German, multicenter cohorts. The prevalence of comorbidities according to WHO ICD-10 classification and drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were identified using AiDKlinik®. RESULTS The analysis included 254 MSA and 363 age- and sex-matched non-ND control patients. MSA patients exhibited a significantly higher burden of comorbidities, in particular diseases of the genitourinary system. Also, more medications were prescribed MSA patients, resulting in a higher prevalence of polypharmacy. Importantly, the risk of potential drug-drug interactions, including severe interactions and contraindicated combinations, was elevated in MSA patients. When comparing MSA-P and MSA-C subtypes, MSA-P patients suffered more frequently from diseases of the genitourinary system and diseases of the musculoskeletal system and connective tissue. CONCLUSIONS MSA patients face a substantial burden of comorbidities, notably in the genitourinary system. This, coupled with increased polypharmacy and potential drug interactions, highlights the complexity of managing MSA patients. Clinicians should carefully consider these factors when devising treatment strategies for MSA patients.
Collapse
Affiliation(s)
- Lan Ye
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
| | - Stephan Greten
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
| | - Florian Wegner
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
| | - Johanna Doll-Lee
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
| | - Lea Krey
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
| | - Johanne Heine
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
| | - Florin Gandor
- Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson, Kliniken Beelitz, 14547, Beelitz-Heilstätten, Germany
| | - Annemarie Vogel
- Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson, Kliniken Beelitz, 14547, Beelitz-Heilstätten, Germany
| | - Luise Berger
- Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson, Kliniken Beelitz, 14547, Beelitz-Heilstätten, Germany
| | - Doreen Gruber
- Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson, Kliniken Beelitz, 14547, Beelitz-Heilstätten, Germany
| | - Johannes Levin
- Department of Neurology, University Hospital of Munich, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany
| | - Sabrina Katzdobler
- Department of Neurology, University Hospital of Munich, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany
| | - Oliver Peters
- German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
- Department of Psychiatry and Psychotherapy, Charité, Universitätsmedizin Berlin, Berlin, Germany
| | - Eman Dashti
- Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Josef Priller
- German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
- Department of Psychiatry and Psychotherapy, Charité, Universitätsmedizin Berlin, Berlin, Germany
- Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany
| | - Eike Jakob Spruth
- German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
- Department of Psychiatry and Psychotherapy, Charité, Universitätsmedizin Berlin, Berlin, Germany
| | - Andrea A Kühn
- German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Charité, Berlin, Germany
| | - Patricia Krause
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Charité, Berlin, Germany
| | - Annika Spottke
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
- Department of Neurology, University Hospital Bonn, Bonn, Germany
| | - Anja Schneider
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
- Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany
| | - Aline Beyle
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
- Department of Neurology, University Hospital Bonn, Bonn, Germany
| | - Okka Kimmich
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
- Department of Neurology, University Hospital Bonn, Bonn, Germany
| | - Markus Donix
- German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany
- Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Robert Haussmann
- Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Moritz Brandt
- German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany
- Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Elisabeth Dinter
- German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany
- Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Jens Wiltfang
- German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
- Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Göttingen, Germany
- Neurosciences and Signaling Group, Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal
| | - Björn H Schott
- German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
- Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Göttingen, Germany
| | - Inga Zerr
- German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
- Department of Neurology, University Medical Center, Georg August University, Göttingen, Germany
| | - Mathias Bähr
- German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
- Department of Neurology, University Medical Center, Georg August University, Göttingen, Germany
| | - Katharina Buerger
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany
| | - Daniel Janowitz
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany
| | - Robert Perneczky
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany
- Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
- Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
| | - Boris-Stephan Rauchmann
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
| | - Endy Weidinger
- Department of Neurology, University Hospital of Munich, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
| | - Emrah Düzel
- German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
- Institute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University, Magdeburg, Germany
- Institute of Cognitive Neuroscience, University College London, London, UK
| | - Wenzel Glanz
- German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
- Institute of Cognitive Neurology and Dementia Research, Otto-Von-Guericke University, Magdeburg, Germany
- Clinic for Neurology, Medical Faculty, University Hospital Magdeburg, Magdeburg, Germany
| | - Stefan Teipel
- German Center for Neurodegenerative Diseases (DZNE), Rostock-Greifswald, Germany
- Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany
| | - Ingo Kilimann
- German Center for Neurodegenerative Diseases (DZNE), Rostock-Greifswald, Germany
- Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany
| | - Isabel Wurster
- German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
- Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
| | - Kathrin Brockmann
- German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
- Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
| | | | - Thomas Klockgether
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
- Department of Neurology, University Hospital Bonn, Bonn, Germany
| | - Olaf Krause
- DIAKOVERE Henriettenstift and Department of General Medicine and Palliative Care, Center for Medicine of the Elderly, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
- Center for Geriatric Medicine, Hospital DIAKOVERE Henriettenstift, Schwe-Mannstrasse 19, 30559, Hannover, Germany
| | - Johannes Heck
- Institute for Clinical Pharmacology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
| | - Günter U Höglinger
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
- Department of Neurology, University Hospital of Munich, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany
| | - Martin Klietz
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
| |
Collapse
|
2
|
Greten S, Wegner F, Jensen I, Krey L, Rogozinski S, Fehring M, Heine J, Doll-Lee J, Pötter-Nerger M, Zeitzschel M, Hagena K, Pedrosa DJ, Eggers C, Bürk K, Trenkwalder C, Claus I, Warnecke T, Süß P, Winkler J, Gruber D, Gandor F, Berg D, Paschen S, Classen J, Pinkhardt EH, Kassubek J, Jost WH, Tönges L, Kühn AA, Schwarz J, Peters O, Dashti E, Priller J, Spruth EJ, Krause P, Spottke A, Schneider A, Beyle A, Kimmich O, Donix M, Haussmann R, Brandt M, Dinter E, Wiltfang J, Schott BH, Zerr I, Bähr M, Buerger K, Janowitz D, Perneczky R, Rauchmann BS, Weidinger E, Levin J, Katzdobler S, Düzel E, Glanz W, Teipel S, Kilimann I, Prudlo J, Gasser T, Brockmann K, Hoffmann DC, Klockgether T, Krause O, Heck J, Höglinger GU, Klietz M. The comorbidity and co-medication profile of patients with progressive supranuclear palsy. J Neurol 2024; 271:782-793. [PMID: 37803149 PMCID: PMC10827866 DOI: 10.1007/s00415-023-12006-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 09/12/2023] [Accepted: 09/14/2023] [Indexed: 10/08/2023]
Abstract
BACKGROUND Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients. OBJECTIVES To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease. METHODS Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were evaluated using AiDKlinik®. RESULTS In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug-drug interactions was higher in PSP patients, especially severe and moderate interactions. CONCLUSIONS PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.
Collapse
Affiliation(s)
- Stephan Greten
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany.
| | - Florian Wegner
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
| | - Ida Jensen
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
| | - Lea Krey
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
| | - Sophia Rogozinski
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
| | - Meret Fehring
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
| | - Johanne Heine
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
| | - Johanna Doll-Lee
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
| | - Monika Pötter-Nerger
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Molly Zeitzschel
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Keno Hagena
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - David J Pedrosa
- Department of Neurology, University Hospital of Marburg and Gießen, 35043, BaldingerstraßeMarburg, Germany
| | - Carsten Eggers
- Department of Neurology, Knappschaftskrankenhaus Bottrop, Osterfelder Str. 157, 46242, Bottrop, Germany
| | - Katrin Bürk
- Kliniken Schmieder Stuttgart-Gerlingen, Solitudestraße 20, 70839, Gerlingen, Germany
| | | | - Inga Claus
- Department of Neurology with Institute of Translational Neurology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany
| | - Tobias Warnecke
- Department of Neurology and Neurorehabilitation, Klinikum Osnabrueck-Academic Teaching Hospital of the WWU Muenster, Am Finkenhügel 1, 49076, Osnabrueck, Germany
| | - Patrick Süß
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schloßplatz 4, 91054, Erlangen, Germany
- Center of Rare Diseases Erlangen (ZSEER), University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schloßplatz 4, 91054, Erlangen, Germany
| | - Jürgen Winkler
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schloßplatz 4, 91054, Erlangen, Germany
- Center of Rare Diseases Erlangen (ZSEER), University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schloßplatz 4, 91054, Erlangen, Germany
| | - Doreen Gruber
- Movement Disorders Hospital, Beelitz-Heilstätten, Straße Nach Fichtenwalde 16, 14547, Beelitz-Heilstätten, Germany
| | - Florin Gandor
- Movement Disorders Hospital, Beelitz-Heilstätten, Straße Nach Fichtenwalde 16, 14547, Beelitz-Heilstätten, Germany
| | - Daniela Berg
- Department of Neurology, Kiel University, Christian-Albrechts-Platz 4, 24118, Kiel, Germany
| | - Steffen Paschen
- Department of Neurology, Kiel University, Christian-Albrechts-Platz 4, 24118, Kiel, Germany
| | - Joseph Classen
- Department of Neurology, University of Leipzig Medical Center, Liebigstraße, 18, 04103, Leipzig, Germany
| | - Elmar H Pinkhardt
- Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
| | - Jan Kassubek
- Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
- German Center for Neurodegenerative Diseases (DZNE), Oberer Eselsberg, 89081, Ulm, Germany
| | - Wolfgang H Jost
- Parkinson-Klinik Ortenau, Kreuzbergstraße 12, 77709, Wolfach, Germany
| | - Lars Tönges
- Department of Neurology, St. Josef-Hospital, Ruhr University Bochum, Gudrunstraße 56, 44791, Bochum, Germany
- Protein Research Unit Ruhr (PURE), Neurodegeneration Research, Ruhr University Bochum, Universitätsstraße 150, 44801, Bochum, Germany
| | - Andrea A Kühn
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Charitépl. 1, 10117, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE), Charitépl. 1, 10117, Berlin, Germany
| | - Johannes Schwarz
- Department of Neurology, Klinik Haag I. OB, Krankenhausstraße 1, 84453, Mühldorf a. Inn, Germany
| | - Oliver Peters
- German Center for Neurodegenerative Diseases (DZNE), Charitépl. 1, 10117, Berlin, Germany
- Department of Psychiatry, Charité-Universitätsmedizin Berlin, Charitépl. 1, 10117, Berlin, Germany
| | - Eman Dashti
- Department of Neurology, Charité-Universitätsmedizin Berlin, Charitépl. 1, 10117, Berlin, Germany
| | - Josef Priller
- German Center for Neurodegenerative Diseases (DZNE), Charitépl. 1, 10117, Berlin, Germany
- Department of Psychiatry and Psychotherapy, Charité, Charitépl. 1, 10117, Berlin, Germany
- Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University Munich, Ismaninger Str. 22, 81675, Munich, Germany
| | - Eike J Spruth
- German Center for Neurodegenerative Diseases (DZNE), Charitépl. 1, 10117, Berlin, Germany
- Department of Psychiatry and Psychotherapy, Charité, Charitépl. 1, 10117, Berlin, Germany
| | - Patricia Krause
- German Center for Neurodegenerative Diseases (DZNE), Charitépl. 1, 10117, Berlin, Germany
| | - Annika Spottke
- German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany
- Department of Neurology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
| | - Anja Schneider
- German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany
- Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
| | - Aline Beyle
- German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany
- Department of Neurology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
| | - Okka Kimmich
- German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany
- Department of Neurology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
| | - Markus Donix
- German Center for Neurodegenerative Diseases (DZNE), Tatzberg 41, 01307, Dresden, Germany
- Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Robert Haussmann
- Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Moritz Brandt
- German Center for Neurodegenerative Diseases (DZNE), Tatzberg 41, 01307, Dresden, Germany
- Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Elisabeth Dinter
- German Center for Neurodegenerative Diseases (DZNE), Tatzberg 41, 01307, Dresden, Germany
- Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Jens Wiltfang
- German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075, Göttingen, Germany
- Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Göttingen, Von-Siebold-Str. 5, 37075, Göttingen, Germany
- Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Campus Universitário de Santiago, 3810-193, Aveiro, Portugal
| | - Björn H Schott
- German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075, Göttingen, Germany
- Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Göttingen, Von-Siebold-Str. 5, 37075, Göttingen, Germany
| | - Inga Zerr
- German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075, Göttingen, Germany
- Department of Neurology, University Medical Center, Georg August University, Von-Siebold-Str. 5, 37075, Göttingen, Germany
| | - Mathias Bähr
- German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075, Göttingen, Germany
- Department of Neurology, University Medical Center, Georg August University, Von-Siebold-Str. 5, 37075, Göttingen, Germany
- Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University Medical Center Göttingen, Von-Siebold-Str. 5, 37075, Göttingen, Germany
| | - Katharina Buerger
- German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
| | - Daniel Janowitz
- German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
| | - Robert Perneczky
- German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy) Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Exhibition Rd, South Kensington, London, SW7 2BX, UK
| | - Boris-Stephan Rauchmann
- German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
| | - Endy Weidinger
- German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Department of Neurology, University Hospital of Munich, Ludwig-Maximilians-Universität (LMU) Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
| | - Johannes Levin
- German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy) Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Department of Neurology, University Hospital of Munich, Ludwig-Maximilians-Universität (LMU) Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
| | - Sabrina Katzdobler
- German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy) Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Department of Neurology, University Hospital of Munich, Ludwig-Maximilians-Universität (LMU) Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
| | - Emrah Düzel
- German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, 39120, Magdeburg, Germany
- Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University, Universitätspl. 2, 39106, Magdeburg, Germany
- Institute of Cognitive Neuroscience, University College London, Gower St, London, WC1E 6BT, UK
| | - Wenzel Glanz
- German Center for Neurodegenerative Diseases (DZNE), Leipziger Straße 44, 39120, Magdeburg, Germany
- Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University, Universitätspl. 2, 39106, Magdeburg, Germany
- Clinic for Neurology, Medical Faculty, University Hospital Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany
| | - Stefan Teipel
- German Center for Neurodegenerative Diseases (DZNE), Gehlsheimer Straße 20, 18147, Rostock-GreifswaldRostock, Germany
- Department of Psychosomatic Medicine, Rostock University Medical Center, Schillingallee 35, 18057, Rostock, Germany
| | - Ingo Kilimann
- German Center for Neurodegenerative Diseases (DZNE), Gehlsheimer Straße 20, 18147, Rostock-GreifswaldRostock, Germany
- Department of Psychosomatic Medicine, Rostock University Medical Center, Schillingallee 35, 18057, Rostock, Germany
| | - Johannes Prudlo
- German Center for Neurodegenerative Diseases (DZNE), Gehlsheimer Straße 20, 18147, Rostock-GreifswaldRostock, Germany
- Department of Neurology, University Medical Center, Schillingallee 35, 18057, Rostock, Germany
| | - Thomas Gasser
- German Center for Neurodegenerative Diseases (DZNE), Otfried-Müller-Straße 23, 72076, Tübingen, Germany
- Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany
| | - Kathrin Brockmann
- German Center for Neurodegenerative Diseases (DZNE), Otfried-Müller-Straße 23, 72076, Tübingen, Germany
- Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany
| | - Daniel C Hoffmann
- German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany
| | - Thomas Klockgether
- German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany
- Department of Neurology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
| | - Olaf Krause
- Center for Medicine of the Elderly, DIAKOVERE Henriettenstift and Department of General Medicine and Palliative Care, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
- Center for Geriatric Medicine, Hospital DIAKOVERE Henriettenstift, Schwemannstrasse 19, 30559, Hannover, Germany
| | - Johannes Heck
- Institute for Clinical Pharmacology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
| | - Günter U Höglinger
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
- German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, 81377, Munich, Germany
- Department of Neurology, University Hospital of Munich, Ludwig-Maximilians-Universität (LMU) Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
| | - Martin Klietz
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany
| |
Collapse
|
3
|
Agostini M, Alexander A, Araujo GR, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Belogurov S, Bettini A, Bezrukov L, Biancacci V, Bossio E, Bothe V, Brudanin V, Brugnera R, Caldwell A, Cattadori C, Chernogorov A, Comellato T, D’Andrea V, Demidova EV, Marco ND, Doroshkevich E, Fischer F, Fomina M, Gangapshev A, Garfagnini A, Gooch C, Grabmayr P, Gurentsov V, Gusev K, Hakenmüller J, Hemmer S, Hofmann W, Huang J, Hult M, Inzhechik LV, Csáthy JJ, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Khushbakht H, Kihm T, Kilgus K, Kirpichnikov IV, Klimenko A, Kneißl R, Knöpfle KT, Kochetov O, Kornoukhov VN, Korošec M, Krause P, Kuzminov VV, Laubenstein M, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Manzanillas L, Marshall G, Misiaszek M, Morella M, Müller Y, Nemchenok I, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Ransom C, Rauscher L, Redchuk M, Riboldi S, Rumyantseva N, Sada C, Salamida F, Schönert S, Schreiner J, Schütt M, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Shtembari L, Simgen H, Smolnikov A, Stukov D, Vasenko AA, Veresnikova A, Vignoli C, Sturm KV, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zatschler B, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. An improved limit on the neutrinoless double-electron capture of 36Ar with GERDA. Eur Phys J C Part Fields 2024; 84:34. [PMID: 38229675 PMCID: PMC10788323 DOI: 10.1140/epjc/s10052-023-12280-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Accepted: 11/21/2023] [Indexed: 01/18/2024]
Abstract
The GERmanium Detector Array (Gerda) experiment operated enriched high-purity germanium detectors in a liquid argon cryostat, which contains 0.33% of 36 Ar, a candidate isotope for the two-neutrino double-electron capture (2ν ECEC) and therefore for the neutrinoless double-electron capture (0ν ECEC). If detected, this process would give evidence of lepton number violation and the Majorana nature of neutrinos. In the radiative 0ν ECEC of 36 Ar, a monochromatic photon is emitted with an energy of 429.88 keV, which may be detected by the Gerda germanium detectors. We searched for the 36 Ar 0ν ECEC with Gerda data, with a total live time of 4.34 year (3.08 year accumulated during Gerda Phase II and 1.26 year during Gerda Phase I). No signal was found and a 90% CL lower limit on the half-life of this process was established T 1 / 2 > 1.5 · 10 22 year. Supplementary Information The online version contains supplementary material available at 10.1140/epjc/s10052-023-12280-6.
Collapse
|
4
|
Krug H, Scharf A, Weber K, Kühn AA, Krause P, Haug S. [Pacemaker, organ or walking stick? Pre-op association with and post-op subjective perception of a deep brain stimulation device]. Fortschr Neurol Psychiatr 2023. [PMID: 38113904 DOI: 10.1055/a-2202-9772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2023]
Abstract
AIM OF THE STUDY This study was conducted in a pre-post design with a survey of patients who had undergone deep brain stimulation (DBS) as treatment for a neurological movement disorder. The aim of the study was to compare patients' expectations and beliefs before a DBS intervention with patients' subjective experience of this intervention. METHODOLOGY The longitudinal study of patients (n=132) with an indication for DBS therapy was based on a written survey at the time points of preoperative screening (pre-op) and one-year follow-up (post-op). RESULTS Preoperatively, a clear majority of respondents believed DSB to be similar to a pacemaker intervention, but one year after the intervention less than one third did so, as they compared DBS to using a walking stick or glasses. CONCLUSION The experience of DBS in the patient's own body seems to be comparable by means of individually different associations, whereby the comparison with non-invasive aids predominates postoperatively. The discussion of these descriptions in the educational interview can contribute to a realistic horizon of patients' expectations before DBS.
Collapse
Affiliation(s)
- Henriette Krug
- Fakultät Gesundheitswissenschaften, MSH Medical School Hamburg University of Applied Sciences and Medical University, Hamburg, Germany
| | - Anna Scharf
- Institut für Sozialforschung und Technikfolgenabschätzung, Ostbayerische Technische Hochschule Regensburg, Regensburg, Germany
| | - Karsten Weber
- Institut für Sozialforschung und Technikfolgenabschätzung, Ostbayerische Technische Hochschule Regensburg, Regensburg, Germany
| | - Andrea A Kühn
- Klinik für Neurologie, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Patricia Krause
- Klinik für Neurologie, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Sonja Haug
- Institut für Sozialforschung und Technikfolgenabschätzung, Ostbayerische Technische Hochschule Regensburg, Regensburg, Germany
| |
Collapse
|
5
|
Busch JL, Kaplan J, Bahners BH, Roediger J, Faust K, Schneider GH, Florin E, Schnitzler A, Krause P, Kühn AA. Local Field Potentials Predict Motor Performance in Deep Brain Stimulation for Parkinson's Disease. Mov Disord 2023; 38:2185-2196. [PMID: 37823518 DOI: 10.1002/mds.29626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Revised: 08/16/2023] [Accepted: 09/19/2023] [Indexed: 10/13/2023] Open
Abstract
BACKGROUND Deep brain stimulation (DBS) is an effective treatment option for patients with Parkinson's disease (PD). However, clinical programming remains challenging with segmented electrodes. OBJECTIVE Using novel sensing-enabled neurostimulators, we investigated local field potentials (LFPs) and their modulation by DBS to assess whether electrophysiological biomarkers may facilitate clinical programming in chronically implanted patients. METHODS Sixteen patients (31 hemispheres) with PD implanted with segmented electrodes in the subthalamic nucleus and a sensing-enabled neurostimulator were included in this study. Recordings were conducted 3 months after DBS surgery following overnight withdrawal of dopaminergic medication. LFPs were acquired while stimulation was turned OFF and during a monopolar review of both directional and ring contacts. Directional beta power and stimulation-induced beta power suppression were computed. Motor performance, as assessed by a pronation-supination task, clinical programming and electrode placement were correlated to directional beta power and stimulation-induced beta power suppression. RESULTS Better motor performance was associated with stronger beta power suppression at higher stimulation amplitudes. Across directional contacts, differences in directional beta power and the extent of stimulation-induced beta power suppression predicted motor performance. However, within individual hemispheres, beta power suppression was superior to directional beta power in selecting the contact with the best motor performance. Contacts clinically activated for chronic stimulation were associated with stronger beta power suppression than non-activated contacts. CONCLUSIONS Our results suggest that stimulation-induced β power suppression is superior to directional β power in selecting the clinically most effective contact. In sum, electrophysiological biomarkers may guide programming of directional DBS systems in PD patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Johannes L Busch
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Junior Clinician Scientist Program, Berlin, Germany
| | - Jonathan Kaplan
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Bahne H Bahners
- Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany
| | - Jan Roediger
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Katharina Faust
- Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Gerd-Helge Schneider
- Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Esther Florin
- Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany
| | - Alfons Schnitzler
- Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany
| | - Patricia Krause
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Andrea A Kühn
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
- NeuroCure, Charité - Universitätsmedizin Berlin, Berlin, Germany
- Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Berlin, Germany
| |
Collapse
|
6
|
Pürner D, Hormozi M, Weiß D, Barbe MT, Jergas H, Prell T, Gülke E, Pötter-Nerger M, Falkenburger B, Klingelhöfer L, Gutsmiedl PK, Haslinger B, Jochim AM, Wolff A, Schröter N, Rijntjes M, van Riesen C, Scheller U, Wolz M, Amouzandeh A, Ebersbach G, Gruber D, Kohl Z, Maetzler W, Paschen S, Pérez-González P, Rozanski V, Schwarz J, Südmeyer M, Torka E, Wesbuer S, Bornmann S, Flöel A, Ip CW, Krause P, Kühn AA, Csoti I, Herting B, van de Loo S, Basheer AA, Liszka R, Jost WH, Koschel J, Haller B, Lingor P. Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease. Neurology 2023; 101:e2078-e2093. [PMID: 37914414 PMCID: PMC10663029 DOI: 10.1212/wnl.0000000000207858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Accepted: 08/14/2023] [Indexed: 11/03/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Advanced therapies (ATs; deep brain stimulation [DBS] or pump therapies: continuous subcutaneous apomorphine infusion [CSAI], levodopa/carbidopa intestinal gel [LCIG]) are used in later stages of Parkinson disease (PD). However, decreasing efficacy over time and/or side effects may require an AT change or combination in individual patients. Current knowledge about changing or combining ATs is limited to mostly retrospective and small-scale studies. The nationwide case collection Combinations of Advanced Therapies in PD assessed simultaneous or sequential AT combinations in Germany since 2005 to analyze their clinical outcome, their side effects, and the reasons for AT modifications. METHODS Data were acquired retrospectively by modular questionnaires in 22 PD centers throughout Germany based on clinical records and comprised general information about the centers/patients, clinical (Mini-Mental Status Test/Montréal Cognitive Assessment, Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale [MDS-UPDRS], side effects, reasons for AT modification), and therapeutical (ATs with specifications, oral medication) data. Data assessment started with initiation of the second AT. RESULTS A total of 148 AT modifications in 116 patients were associated with significantly improved objective (median decrease of MDS-UPDRS Part III 4.0 points [p < 0.001], of MDS-UPDRS Part IV 6.0 points [p < 0.001], of MDS-UPDRS Part IV-off-time item 1.0 points [p < 0.001]) and subjective clinical outcome and decreasing side effect rates. Main reasons for an AT modification were insufficient symptom control and side effects of the previous therapy. Subgroup analyses suggest addition of DBS in AT patients with leading dyskinesia, addition of LCIG for leading other cardinal motor symptoms, and addition of LCIG or CSAI for dominant off-time. The most long-lasting therapy-until requiring a modification-was DBS. DISCUSSION Changing or combining ATs may be beneficial when 1 AT is insufficient in efficacy or side effects. The outcome of an AT combination is comparable with the clinical benefit by introducing the first AT. The added AT should be chosen dependent on dominant clinical symptoms and adverse effects. Furthermore, prospective trials are needed to confirm the results of this exploratory case collection. CLASSIFICATION OF EVIDENCE This study provides Class IV evidence that, in patients with PD, changing or combining ATs is associated with an improvement in the MDS-UPDRS or subjective symptom reporting.
Collapse
Affiliation(s)
- Dominik Pürner
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Mohammad Hormozi
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Daniel Weiß
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Michael T Barbe
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Hannah Jergas
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Tino Prell
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Eileen Gülke
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Monika Pötter-Nerger
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Björn Falkenburger
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Lisa Klingelhöfer
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Pia K Gutsmiedl
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Bernhard Haslinger
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Angela M Jochim
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Andreas Wolff
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Nils Schröter
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Michel Rijntjes
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Christoph van Riesen
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Ute Scheller
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Martin Wolz
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Ali Amouzandeh
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Georg Ebersbach
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Doreen Gruber
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Zacharias Kohl
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Walter Maetzler
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Steffen Paschen
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Pablo Pérez-González
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Verena Rozanski
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Johannes Schwarz
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Martin Südmeyer
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Elisabeth Torka
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Simone Wesbuer
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Sarah Bornmann
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Agnes Flöel
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Chi Wang Ip
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Patricia Krause
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Andrea A Kühn
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Ilona Csoti
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Birgit Herting
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Simone van de Loo
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Aniz Ahammed Basheer
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Robert Liszka
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Wolfgang H Jost
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Jiri Koschel
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Bernhard Haller
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany
| | - Paul Lingor
- From the Klinik und Poliklinik für Neurologie (D.P., P.K.G., B. Haslinger, A.M.J., A.W., P.L.), Klinikum rechts der Isar der TU München, Munich; Neurologische Universitätsklinik (M.H., D.W.), Universitätsklinikum Tübingen; Klinik und Poliklinik für Neurologie (M.T.B., H.J.), Uniklinik Köln, Cologne; Klinik für Neurologie (T.P.), Universitätsklinikum Jena; Universitätsklinik und Poliklinik für Altersmedizin (T.P.), Universitätsmedizin Halle (Saale); Klinik und Poliklinik für Neurologie (E.G., M.P.-N.), Universitätsklinikum Hamburg-Eppendorf, Hamburg; Klinik und Poliklinik für Neurologie (B.F., L.K.), Universitätsklinikum Carl Gustav Carus an der TU Dresden; Klinik für Neurologie und Neurophysiologie (N.S., M.R.), Universitätsklinikum Freiburg; Klinik für Neurologie (C.v.R., U.S.), Universitätsmedizin Göttingen; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (C.v.R.), Standort Göttingen; Klinik für Neurologie (M.W.), Elblandklinikum Meißen, Meissen; Klinik für Neurologie (A.A., M.S.), Klinikum Ernst von Bergmann Potsdam; Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson (G.E., D.G.), Beelitz-Heilstätten, Beelitz; Klinik und Poliklinik für Neurologie der Universität Regensburg am medbo Bezirksklinikum Regensburg (Z.K., E.T.); Klinik für Neurologie (W.M., S.P.), Universitätsklinikum Schleswig-Holstein, Campus Kiel; Klinik für Neurologie (P.P.-G., S.W.), Christophorus-Klinik Dülmen; Parkinson Fachklinik Haag i. OB (V.R., J.S.); Klinik und Poliklinik für Neurologie (S.B., A.F.), Universitätsmedizin Greifswald; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (A.F.), Standort Rostock/Greifswald; Neurologische Klinik und Poliklinik (C.W.I.), Universitätsklinikum Würzburg; Klinik für Neurologie (P.K.), Charité-Universitätsmedizin Berlin; Klinik für Neurologie (A.A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Cluster of Excellence, Berlin; Gertrudis-Klinik Biskirchen (I.C.), Parkinson-Zentrum, Leun-Biskirchen; Klinik für Neurologie und Gerontoneurologie (B. Herting, S.v.d.L.), DIAKONEO Diak Klinikum, Diakonie-Klinikum Schwäbisch Hall; Klinik für Neurologie (A.A.B., R.L.), Marienhaus Klinikum St. Wendel-Ottweiler; Parkinson-Klinik Ortenau (W.H.J., J.K.), Wolfach; Institut für KI und Informatik in der Medizin (B. Haller), Klinikum rechts der Isar der TU München, Munich; Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (P.L.), Standort München, Munich; and Munich Cluster for Systems Neurology (SyNergy) (P.L.), Germany.
| |
Collapse
|
7
|
Agostini M, Alexander A, Araujo GR, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Belogurov S, Bettini A, Bezrukov L, Biancacci V, Bossio E, Bothe V, Brugnera R, Caldwell A, Calgaro S, Cattadori C, Chernogorov A, Chiu PJ, Comellato T, D'Andrea V, Demidova EV, Di Giacinto A, Di Marco N, Doroshkevich E, Fischer F, Fomina M, Gangapshev A, Garfagnini A, Gooch C, Grabmayr P, Gurentsov V, Gusev K, Hackenmüller S, Hemmer S, Hofmann W, Huang J, Hult M, Inzhechik LV, Janicskó Csáthy J, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Khushbakht H, Kihm T, Kilgus K, Kirpichnikov IV, Klimenko A, Knöpfle KT, Kochetov O, Kornoukhov VN, Krause P, Kuzminov VV, Laubenstein M, Lehnert B, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Manzanillas L, Marshall G, Miloradovic M, Mingazheva R, Misiaszek M, Morella M, Müller Y, Nemchenok I, Neuberger M, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Ransom C, Rauscher L, Redchuk M, Riboldi S, Rumyantseva N, Sada C, Sailer S, Salamida F, Schönert S, Schreiner J, Schütt M, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Shtembari L, Simgen H, Smolnikov A, Stukov D, Sullivan S, Vasenko AA, Veresnikova A, Vignoli C, von Sturm K, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zatschler B, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. Final Results of GERDA on the Two-Neutrino Double-β Decay Half-Life of ^{76}Ge. Phys Rev Lett 2023; 131:142501. [PMID: 37862664 DOI: 10.1103/physrevlett.131.142501] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2023] [Accepted: 08/15/2023] [Indexed: 10/22/2023]
Abstract
We present the measurement of the two-neutrino double-β decay rate of ^{76}Ge performed with the GERDA Phase II experiment. With a subset of the entire GERDA exposure, 11.8 kg yr, the half-life of the process has been determined: T_{1/2}^{2ν}=(2.022±0.018_{stat}±0.038_{syst})×10^{21} yr. This is the most precise determination of the ^{76}Ge two-neutrino double-β decay half-life and one of the most precise measurements of a double-β decay process. The relevant nuclear matrix element can be extracted: M_{eff}^{2ν}=(0.101±0.001).
Collapse
Affiliation(s)
- M Agostini
- Department of Physics and Astronomy, University College London, London, United Kingdom
| | - A Alexander
- Department of Physics and Astronomy, University College London, London, United Kingdom
| | - G R Araujo
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - A M Bakalyarov
- National Research Centre "Kurchatov Institute," Moscow, Russia
| | - M Balata
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - I Barabanov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - L Baudis
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - C Bauer
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - S Belogurov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute," Moscow, Russia
| | - A Bettini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - L Bezrukov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - V Biancacci
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - E Bossio
- Physik Department, Technische Universität München, Germany
| | - V Bothe
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - R Brugnera
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - A Caldwell
- Max-Planck-Institut für Physik, Munich, Germany
| | - S Calgaro
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | | | - A Chernogorov
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute," Moscow, Russia
- National Research Centre "Kurchatov Institute," Moscow, Russia
| | - P-J Chiu
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - T Comellato
- Physik Department, Technische Universität München, Germany
| | - V D'Andrea
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, L'Aquila, Italy
| | - E V Demidova
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute," Moscow, Russia
| | - A Di Giacinto
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - N Di Marco
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - E Doroshkevich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F Fischer
- Max-Planck-Institut für Physik, Munich, Germany
| | - M Fomina
- Joint Institute for Nuclear Research, Dubna, Russia
| | - A Gangapshev
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Garfagnini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - C Gooch
- Max-Planck-Institut für Physik, Munich, Germany
| | - P Grabmayr
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - V Gurentsov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K Gusev
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre "Kurchatov Institute," Moscow, Russia
- Physik Department, Technische Universität München, Germany
| | | | | | - W Hofmann
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - J Huang
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - M Hult
- European Commission, JRC-Geel, Geel, Belgium
| | - L V Inzhechik
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | | | - J Jochum
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - M Junker
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - V Kazalov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - Y Kermaïdic
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - H Khushbakht
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - T Kihm
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - K Kilgus
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - I V Kirpichnikov
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute," Moscow, Russia
| | - A Klimenko
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - K T Knöpfle
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - O Kochetov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - V N Kornoukhov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - P Krause
- Physik Department, Technische Universität München, Germany
| | - V V Kuzminov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Laubenstein
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - B Lehnert
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | | | - B Lubsandorzhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - G Lutter
- European Commission, JRC-Geel, Geel, Belgium
| | - C Macolino
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, L'Aquila, Italy
| | | | - W Maneschg
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | - G Marshall
- Department of Physics and Astronomy, University College London, London, United Kingdom
| | - M Miloradovic
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - R Mingazheva
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - M Misiaszek
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - M Morella
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - Y Müller
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - I Nemchenok
- Joint Institute for Nuclear Research, Dubna, Russia
| | - M Neuberger
- Physik Department, Technische Universität München, Germany
| | - L Pandola
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - K Pelczar
- European Commission, JRC-Geel, Geel, Belgium
| | - L Pertoldi
- Physik Department, Technische Universität München, Germany
- INFN Padova, Padua, Italy
| | - P Piseri
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - A Pullia
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - C Ransom
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - L Rauscher
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | | | - S Riboldi
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - N Rumyantseva
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre "Kurchatov Institute," Moscow, Russia
| | - C Sada
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - S Sailer
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - F Salamida
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, L'Aquila, Italy
| | - S Schönert
- Physik Department, Technische Universität München, Germany
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - M Schütt
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A-K Schütz
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - O Schulz
- Max-Planck-Institut für Physik, Munich, Germany
| | - M Schwarz
- Physik Department, Technische Universität München, Germany
| | | | - O Selivanenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - E Shevchik
- Joint Institute for Nuclear Research, Dubna, Russia
| | - M Shirchenko
- Joint Institute for Nuclear Research, Dubna, Russia
| | - L Shtembari
- Max-Planck-Institut für Physik, Munich, Germany
| | - H Simgen
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A Smolnikov
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - D Stukov
- National Research Centre "Kurchatov Institute," Moscow, Russia
| | - S Sullivan
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A A Vasenko
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute," Moscow, Russia
| | - A Veresnikova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C Vignoli
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - K von Sturm
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - T Wester
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - C Wiesinger
- Physik Department, Technische Universität München, Germany
| | - M Wojcik
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - E Yanovich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - B Zatschler
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - I Zhitnikov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - S V Zhukov
- National Research Centre "Kurchatov Institute," Moscow, Russia
| | - D Zinatulina
- Joint Institute for Nuclear Research, Dubna, Russia
| | - A Zschocke
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | | | - K Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - G Zuzel
- Institute of Physics, Jagiellonian University, Cracow, Poland
| |
Collapse
|
8
|
Barra ME, Iracheta C, Tolland J, Jehle J, Minova L, Li K, Amatangelo M, Krause P, Batra A, Vaitkevicius H. Multidisciplinary Approach to Sedation and Early Mobility of Intubated Critically Ill Neurologic Patients Improves Mobility at Discharge. Neurohospitalist 2023; 13:351-360. [PMID: 37701262 PMCID: PMC10494812 DOI: 10.1177/19418744231182897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/14/2023] Open
Abstract
Background and Purpose Over-sedation may confound neurologic assessment in critically ill neurologic patients and prolong duration of mechanical ventilation (MV). Decreased sedative use may facilitate early functional independence when combined with early mobility. The objective of this study was to evaluate the impact of a stepwise, multidisciplinary analgesia-first sedation pathway and early mobility protocol on medication use and mobility in the neuroscience intensive care unit (ICU). Methods We performed a single-center prospective cohort study with adult patients admitted to a neuroscience ICU between March and June 2016-2018 who required MV for greater than 48 hours. Patients were included from three separate phases of the study: Phase I - historical controls (2016); Phase II - analgesia-first pathway (2017); Phase III - early mobility protocol (2018). Primary outcomes included propofol requirements during MV, total rehabilitation therapy provided, and functional mobility during ICU admission. Results 156 patients were included in the analysis. Decreasing propofol exposure was observed during Phase I, II, and III (median 2243.7 mg/day vs 2065.6 mg/day vs 1360.8 mg/day, respectively; P = .04 between Phase I and III). Early mobility was provided in 59.7%, 40%, and 81.6% of patients while admitted to the ICU in Phase I, II, and III, respectively (P < .01). An increased proportion of patients in Phase III were walking or ambulating at ICU discharge (26.7%; 8/30) compared to Phase I (7.9%, 3/38, P = .05). Conclusions An interdisciplinary approach with an analgesia-first sedation pathway with early mobility protocol was associated with less sedative use, increased rehabilitation therapy, and improved functional mobility status at ICU discharge.
Collapse
Affiliation(s)
- Megan E. Barra
- Department of Pharmacy, Massachusetts General Hospital, Boston, MA USA
| | - Christine Iracheta
- Department of Rehabilitation Services, Brigham and Women’s Hospital, Boston, MA USA
| | - Joseph Tolland
- Department of Rehabilitation Services, Brigham and Women’s Hospital, Boston, MA USA
| | - Johnathan Jehle
- Department of Neurology, Brigham and Women’s Hospital, Boston, MA USA
- Department of Adult Palliative Care, Brigham and Women’s Hospital, Boston, MA USA
| | - Ljubica Minova
- Department of Pharmacy, Massachusetts General Hospital, Boston, MA USA
| | - Karen Li
- Department of Neurology, Brigham and Women’s Hospital, Boston, MA USA
| | - Mary Amatangelo
- Department of Neurology, Brigham and Women’s Hospital, Boston, MA USA
| | - Patricia Krause
- Department of Pharmacy, Brigham and Women’s Hospital, Boston, MA USA
| | - Ayush Batra
- Department of Neurology & Pathology, Northwestern University Feinberg School of Medicine, Chicago IL USA
| | | |
Collapse
|
9
|
Merk T, Köhler R, Peterson V, Lyra L, Vanhoecke J, Chikermane M, Binns T, Li N, Walton A, Bush A, Sisterson N, Busch J, Lofredi R, Habets J, Huebl J, Zhu G, Yin Z, Zhao B, Merkl A, Bajbouj M, Krause P, Faust K, Schneider GH, Horn A, Zhang J, Kühn A, Richardson RM, Neumann WJ. Invasive neurophysiology and whole brain connectomics for neural decoding in patients with brain implants. Res Sq 2023:rs.3.rs-3212709. [PMID: 37790428 PMCID: PMC10543023 DOI: 10.21203/rs.3.rs-3212709/v1] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/05/2023]
Abstract
Brain computer interfaces (BCI) provide unprecedented spatiotemporal precision that will enable significant expansion in how numerous brain disorders are treated. Decoding dynamic patient states from brain signals with machine learning is required to leverage this precision, but a standardized framework for identifying and advancing novel clinical BCI approaches does not exist. Here, we developed a platform that integrates brain signal decoding with connectomics and demonstrate its utility across 123 hours of invasively recorded brain data from 73 neurosurgical patients treated for movement disorders, depression and epilepsy. First, we introduce connectomics-informed movement decoders that generalize across cohorts with Parkinson's disease and epilepsy from the US, Europe and China. Next, we reveal network targets for emotion decoding in left prefrontal and cingulate circuits in DBS patients with major depression. Finally, we showcase opportunities to improve seizure detection in responsive neurostimulation for epilepsy. Our platform provides rapid, high-accuracy decoding for precision medicine approaches that can dynamically adapt neuromodulation therapies in response to the individual needs of patients.
Collapse
|
10
|
Agostini M, Alexander A, Araujo G, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Belogurov S, Bettini A, Bezrukov L, Biancacci V, Bossio E, Bothe V, Brugnera R, Caldwell A, Calgaro S, Cattadori C, Chernogorov A, Chiu PJ, Comellato T, D’Andrea V, Demidova EV, Di Giacinto A, Di Marco N, Doroshkevich E, Fischer F, Fomina M, Gangapshev A, Garfagnini A, Gooch C, Grabmayr P, Gurentsov V, Gusev K, Hakenmüller J, Hemmer S, Hofmann W, Hult M, Inzhechik LV, Janicskó Csáthy J, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Khushbakht H, Kihm T, Kilgus K, Kirpichnikov IV, Klimenko A, Knöpfle KT, Kochetov O, Kornoukhov VN, Krause P, Kuzminov VV, Laubenstein M, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Manzanillas L, Marshall G, Misiaszek M, Morella M, Müller Y, Nemchenok I, Neuberger M, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Rauscher L, Redchuk M, Riboldi S, Rumyantseva N, Sada C, Sailer S, Salamida F, Schönert S, Schreiner J, Schütt M, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Shtembari L, Simgen H, Smolnikov A, Stukov D, Sullivan S, Vasenko AA, Veresnikova A, Vignoli C, von Sturm K, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zatschler B, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. Search for tri-nucleon decays of 76Ge in GERDA. Eur Phys J C Part Fields 2023; 83:778. [PMID: 37674593 PMCID: PMC10477131 DOI: 10.1140/epjc/s10052-023-11862-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Accepted: 07/25/2023] [Indexed: 09/08/2023]
Abstract
We search for tri-nucleon decays of 76 Ge in the dataset from the GERmanium Detector Array (GERDA) experiment. Decays that populate excited levels of the daughter nucleus above the threshold for particle emission lead to disintegration and are not considered. The ppp-, ppn-, and pnn-decays lead to 73 Cu, 73 Zn, and 73 Ga nuclei, respectively. These nuclei are unstable and eventually proceed by the beta decay of 73 Ga to 73 Ge (stable). We search for the 73 Ga decay exploiting the fact that it dominantly populates the 66.7 keV 73 m Ga state with half-life of 0.5 s. The nnn-decays of 76 Ge that proceed via 73 m Ge are also included in our analysis. We find no signal candidate and place a limit on the sum of the decay widths of the inclusive tri-nucleon decays that corresponds to a lower lifetime limit of 1.2× 1026 yr (90% credible interval). This result improves previous limits for tri-nucleon decays by one to three orders of magnitude.
Collapse
Affiliation(s)
- M. Agostini
- Department of Physics and Astronomy, University College London, London, UK
| | - A. Alexander
- Department of Physics and Astronomy, University College London, London, UK
| | - G. Araujo
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | | | - M. Balata
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - I. Barabanov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - L. Baudis
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - C. Bauer
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - S. Belogurov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
- NRNU MEPhI, Moscow, Russia
| | - A. Bettini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - L. Bezrukov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - V. Biancacci
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - E. Bossio
- Physik Department, Technische Universität München, Munich, Germany
| | - V. Bothe
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - R. Brugnera
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - A. Caldwell
- Max-Planck-Institut für Physik, Munich, Germany
| | - S. Calgaro
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | | | - A. Chernogorov
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - P.-J. Chiu
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - T. Comellato
- Physik Department, Technische Universität München, Munich, Germany
| | - V. D’Andrea
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | - E. V. Demidova
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Di Giacinto
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - N. Di Marco
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - E. Doroshkevich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F. Fischer
- Max-Planck-Institut für Physik, Munich, Germany
| | - M. Fomina
- Joint Institute for Nuclear Research, Dubna, Russia
| | - A. Gangapshev
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A. Garfagnini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - C. Gooch
- Max-Planck-Institut für Physik, Munich, Germany
| | - P. Grabmayr
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - V. Gurentsov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K. Gusev
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
- Physik Department, Technische Universität München, Munich, Germany
| | - J. Hakenmüller
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Present Address: Duke University, Durham, NC USA
| | | | - W. Hofmann
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - M. Hult
- European Commission, JRC-Geel, Geel, Belgium
| | - L. V. Inzhechik
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Moscow Institute of Physics and Technology, Moscow, Russia
| | - J. Janicskó Csáthy
- Physik Department, Technische Universität München, Munich, Germany
- Present Address: Leibniz-Institut für Kristallzüchtung, Berlin, Germany
| | - J. Jochum
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - M. Junker
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - V. Kazalov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - Y. Kermaïdic
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - H. Khushbakht
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - T. Kihm
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - K. Kilgus
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - I. V. Kirpichnikov
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Klimenko
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Dubna State University, Dubna, Russia
| | - K. T. Knöpfle
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - O. Kochetov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - V. N. Kornoukhov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- NRNU MEPhI, Moscow, Russia
| | - P. Krause
- Physik Department, Technische Universität München, Munich, Germany
| | - V. V. Kuzminov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Laubenstein
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - M. Lindner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | | | - B. Lubsandorzhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - G. Lutter
- European Commission, JRC-Geel, Geel, Belgium
| | - C. Macolino
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | | | - W. Maneschg
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | - G. Marshall
- Department of Physics and Astronomy, University College London, London, UK
| | - M. Misiaszek
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - M. Morella
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - Y. Müller
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - I. Nemchenok
- Joint Institute for Nuclear Research, Dubna, Russia
- Dubna State University, Dubna, Russia
| | - M. Neuberger
- Physik Department, Technische Universität München, Munich, Germany
| | - L. Pandola
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - K. Pelczar
- European Commission, JRC-Geel, Geel, Belgium
| | - L. Pertoldi
- Physik Department, Technische Universität München, Munich, Germany
- INFN Padova, Padua, Italy
| | - P. Piseri
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - A. Pullia
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - L. Rauscher
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | | | - S. Riboldi
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - N. Rumyantseva
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - C. Sada
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - S. Sailer
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - F. Salamida
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | - S. Schönert
- Physik Department, Technische Universität München, Munich, Germany
| | - J. Schreiner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - M. Schütt
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A.-K. Schütz
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - O. Schulz
- Max-Planck-Institut für Physik, Munich, Germany
| | - M. Schwarz
- Physik Department, Technische Universität München, Munich, Germany
| | | | - O. Selivanenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - E. Shevchik
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | - H. Simgen
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A. Smolnikov
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - D. Stukov
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - S. Sullivan
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A. A. Vasenko
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Veresnikova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C. Vignoli
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - K. von Sturm
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - T. Wester
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | | | - M. Wojcik
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - E. Yanovich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - B. Zatschler
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - I. Zhitnikov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - S. V. Zhukov
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | | | - A. Zschocke
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | | | - K. Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - G. Zuzel
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | | |
Collapse
|
11
|
Al-Fatly B, Giesler SJ, Oxenford S, Li N, Dembek TA, Achtzehn J, Krause P, Visser-Vandewalle V, Krauss JK, Runge J, Tadic V, Bäumer T, Schnitzler A, Vesper J, Wirths J, Timmermann L, Kühn AA, Koy A. Neuroimaging-based analysis of DBS outcomes in pediatric dystonia: Insights from the GEPESTIM registry. Neuroimage Clin 2023; 39:103449. [PMID: 37321142 PMCID: PMC10275720 DOI: 10.1016/j.nicl.2023.103449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Revised: 05/16/2023] [Accepted: 06/02/2023] [Indexed: 06/17/2023]
Abstract
INTRODUCTION Deep brain stimulation (DBS) is an established treatment in patients of various ages with pharmaco-resistant neurological disorders. Surgical targeting and postoperative programming of DBS depend on the spatial location of the stimulating electrodes in relation to the surrounding anatomical structures, and on electrode connectivity to a specific distribution pattern within brain networks. Such information is usually collected using group-level analysis, which relies on the availability of normative imaging resources (atlases and connectomes). Analysis of DBS data in children with debilitating neurological disorders such as dystonia would benefit from such resources, especially given the developmental differences in neuroimaging data between adults and children. We assembled pediatric normative neuroimaging resources from open-access datasets in order to comply with age-related anatomical and functional differences in pediatric DBS populations. We illustrated their utility in a cohort of children with dystonia treated with pallidal DBS. We aimed to derive a local pallidal sweetspot and explore a connectivity fingerprint associated with pallidal stimulation to exemplify the utility of the assembled imaging resources. METHODS An average pediatric brain template (the MNI brain template 4.5-18.5 years) was implemented and used to localize the DBS electrodes in 20 patients from the GEPESTIM registry cohort. A pediatric subcortical atlas, analogous to the DISTAL atlas known in DBS research, was also employed to highlight the anatomical structures of interest. A local pallidal sweetspot was modeled, and its degree of overlap with stimulation volumes was calculated as a correlate of individual clinical outcomes. Additionally, a pediatric functional connectome of 100 neurotypical subjects from the Consortium for Reliability and Reproducibility was built to allow network-based analyses and decipher a connectivity fingerprint responsible for the clinical improvements in our cohort. RESULTS We successfully implemented a pediatric neuroimaging dataset that will be made available for public use as a tool for DBS analyses. Overlap of stimulation volumes with the identified DBS-sweetspot model correlated significantly with improvement on a local spatial level (R = 0.46, permuted p = 0.019). The functional connectivity fingerprint of DBS outcomes was determined to be a network correlate of therapeutic pallidal stimulation in children with dystonia (R = 0.30, permuted p = 0.003). CONCLUSIONS Local sweetspot and distributed network models provide neuroanatomical substrates for DBS-associated clinical outcomes in dystonia using pediatric neuroimaging surrogate data. Implementation of this pediatric neuroimaging dataset might help to improve the practice and pave the road towards a personalized DBS-neuroimaging analyses in pediatric patients.
Collapse
Affiliation(s)
- Bassam Al-Fatly
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany.
| | - Sabina J Giesler
- Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Simon Oxenford
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany
| | - Ningfei Li
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany
| | - Till A Dembek
- Department of Neurology, Faculty of Medicine, University of Cologne, Cologne, Germany
| | - Johannes Achtzehn
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany
| | - Patricia Krause
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany
| | - Veerle Visser-Vandewalle
- Department of Stereotactic and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Joachim K Krauss
- Department of Neurosurgery, Hannover Medical School, Hannover, Germany
| | - Joachim Runge
- Department of Neurosurgery, Hannover Medical School, Hannover, Germany
| | - Vera Tadic
- Department of Neurology, University Medical Center Schleswig Holstein, Lübeck Campus, Lübeck, Germany
| | - Tobias Bäumer
- Institute of System Motor Science, University Medical Center Schleswig Holstein, Lübeck Campus, Lübeck, Germany
| | - Alfons Schnitzler
- Department of Neurology, Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Jan Vesper
- Department of Neurology, Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Jochen Wirths
- Department of Stereotactic and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Lars Timmermann
- Department of Neurology, University Hospital of Marburg, Marburg, Germany
| | - Andrea A Kühn
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany.
| | - Anne Koy
- Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Rare Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| |
Collapse
|
12
|
Agostini M, Alexander A, Araujo GR, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Belogurov S, Bettini A, Bezrukov L, Biancacci V, Bossio E, Bothe V, Brugnera R, Caldwell A, Calgaro S, Cattadori C, Chernogorov A, Chiu PJ, Comellato T, D’Andrea V, Demidova EV, Di Giacinto A, Di Marco N, Doroshkevich E, Fischer F, Fomina M, Gangapshev A, Garfagnini A, Gooch C, Grabmayr P, Gurentsov V, Gusev K, Hakenmüller J, Hemmer S, Hofmann W, Hult M, Inzhechik LV, Csáthy JJ, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Khushbakht H, Kihm T, Kilgus K, Kirpichnikov IV, Klimenko A, Knöpfle KT, Kochetov O, Kornoukhov VN, Krause P, Kuzminov VV, Laubenstein M, Lehnert B, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Manzanillas L, Marshall G, Miloradovic M, Mingazheva R, Misiaszek M, Morella M, Müller Y, Nemchenok I, Neuberger M, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Rauscher L, Redchuk M, Riboldi S, Rumyantseva N, Sada C, Sailer S, Salamida F, Schönert S, Schreiner J, Schütt M, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Shtembari L, Simgen H, Smolnikov A, Stukov D, Sullivan S, Vasenko AA, Veresnikova A, Vignoli C, von Sturm K, Wegmann A, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zatschler B, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. Liquid argon light collection and veto modeling in GERDA Phase II. Eur Phys J C Part Fields 2023; 83:319. [PMID: 37122826 PMCID: PMC10126063 DOI: 10.1140/epjc/s10052-023-11354-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Accepted: 02/24/2023] [Indexed: 05/03/2023]
Abstract
The ability to detect liquid argon scintillation light from within a densely packed high-purity germanium detector array allowed the Gerda experiment to reach an exceptionally low background rate in the search for neutrinoless double beta decay of76 Ge. Proper modeling of the light propagation throughout the experimental setup, from any origin in the liquid argon volume to its eventual detection by the novel light read-out system, provides insight into the rejection capability and is a necessary ingredient to obtain robust background predictions. In this paper, we present a model of the Gerda liquid argon veto, as obtained by Monte Carlo simulations and constrained by calibration data, and highlight its application for background decomposition.
Collapse
Affiliation(s)
- M. Agostini
- Department of Physics and Astronomy, University College London, London, UK
| | - A. Alexander
- Department of Physics and Astronomy, University College London, London, UK
| | - G. R. Araujo
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | | | - M. Balata
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - I. Barabanov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - L. Baudis
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - C. Bauer
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - S. Belogurov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
- Moscow Inst. of Physics and Technology, Dolgoprudny, Russia
| | - A. Bettini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - L. Bezrukov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - V. Biancacci
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - E. Bossio
- Physik Department, Technische Universität München, Munich, Germany
| | - V. Bothe
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - R. Brugnera
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - A. Caldwell
- Max-Planck-Institut für Physik, Munich, Germany
| | - S. Calgaro
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | | | - A. Chernogorov
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - P. -J. Chiu
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - T. Comellato
- Physik Department, Technische Universität München, Munich, Germany
| | - V. D’Andrea
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | - E. V. Demidova
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Di Giacinto
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - N. Di Marco
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - E. Doroshkevich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F. Fischer
- Max-Planck-Institut für Physik, Munich, Germany
| | - M. Fomina
- Joint Institute for Nuclear Research, Dubna, Russia
| | - A. Gangapshev
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A. Garfagnini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - C. Gooch
- Max-Planck-Institut für Physik, Munich, Germany
| | - P. Grabmayr
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - V. Gurentsov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K. Gusev
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
- Physik Department, Technische Universität München, Munich, Germany
| | - J. Hakenmüller
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Present Address: Duke University, Durham, NC USA
| | | | - W. Hofmann
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - M. Hult
- European Commission, JRC-Geel, Geel, Belgium
| | - L. V. Inzhechik
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Dubna State University, Dubna, Russia
| | - J. Janicskó Csáthy
- Physik Department, Technische Universität München, Munich, Germany
- Present Address: Leibniz-Institut für Kristallzüchtung, Berlin, Germany
| | - J. Jochum
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - M. Junker
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - V. Kazalov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - Y. Kermaïdic
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Present Address: Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - H. Khushbakht
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - T. Kihm
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - K. Kilgus
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - I. V. Kirpichnikov
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Klimenko
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Dubna State University, Dubna, Russia
| | - K. T. Knöpfle
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- NRNU MEPhI, Moscow, Russia
| | - O. Kochetov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - V. N. Kornoukhov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - P. Krause
- Physik Department, Technische Universität München, Munich, Germany
| | - V. V. Kuzminov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Laubenstein
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - B. Lehnert
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
- Present Address: Nuclear Science Division, Berkeley, USA
| | - M. Lindner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | | | - B. Lubsandorzhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - G. Lutter
- European Commission, JRC-Geel, Geel, Belgium
| | - C. Macolino
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | | | - W. Maneschg
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | - G. Marshall
- Department of Physics and Astronomy, University College London, London, UK
| | - M. Miloradovic
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - R. Mingazheva
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - M. Misiaszek
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - M. Morella
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - Y. Müller
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - I. Nemchenok
- Joint Institute for Nuclear Research, Dubna, Russia
- Present Address: Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - M. Neuberger
- Physik Department, Technische Universität München, Munich, Germany
| | - L. Pandola
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - K. Pelczar
- European Commission, JRC-Geel, Geel, Belgium
| | - L. Pertoldi
- Physik Department, Technische Universität München, Munich, Germany
- INFN Padova, Padua, Italy
| | - P. Piseri
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - A. Pullia
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - L. Rauscher
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | | | - S. Riboldi
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - N. Rumyantseva
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - C. Sada
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - S. Sailer
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - F. Salamida
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | - S. Schönert
- Physik Department, Technische Universität München, Munich, Germany
| | - J. Schreiner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - M. Schütt
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A. -K. Schütz
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - O. Schulz
- Max-Planck-Institut für Physik, Munich, Germany
| | - M. Schwarz
- Physik Department, Technische Universität München, Munich, Germany
| | | | - O. Selivanenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - E. Shevchik
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | - H. Simgen
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A. Smolnikov
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - D. Stukov
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - S. Sullivan
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A. A. Vasenko
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Veresnikova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C. Vignoli
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
| | - K. von Sturm
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - A. Wegmann
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - T. Wester
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - C. Wiesinger
- Physik Department, Technische Universität München, Munich, Germany
| | - M. Wojcik
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - E. Yanovich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - B. Zatschler
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - I. Zhitnikov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - S. V. Zhukov
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | | | - A. Zschocke
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | | | - K. Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - G. Zuzel
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - Gerda collaboration
- INFN Laboratori Nazionali del Gran Sasso, Assergi, Italy
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
- INFN Laboratori Nazionali del Sud, Catania, Italy
- Institute of Physics, Jagiellonian University, Cracow, Poland
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
- Joint Institute for Nuclear Research, Dubna, Russia
- European Commission, JRC-Geel, Geel, Belgium
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Department of Physics and Astronomy, University College London, London, UK
- INFN Milano Bicocca, Milan, Italy
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
- Max-Planck-Institut für Physik, Munich, Germany
- Physik Department, Technische Universität München, Munich, Germany
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
- Physik-Institut, Universität Zürich, Zurich, Switzerland
- Present Address: Duke University, Durham, NC USA
- Present Address: Leibniz-Institut für Kristallzüchtung, Berlin, Germany
- Present Address: Nuclear Science Division, Berkeley, USA
- Present Address: Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
- NRNU MEPhI, Moscow, Russia
- Moscow Inst. of Physics and Technology, Dolgoprudny, Russia
- Dubna State University, Dubna, Russia
| |
Collapse
|
13
|
Roediger J, Dembek TA, Achtzehn J, Busch JL, Krämer AP, Faust K, Schneider GH, Krause P, Horn A, Kühn AA. Automated deep brain stimulation programming based on electrode location: a randomised, crossover trial using a data-driven algorithm. Lancet Digit Health 2023; 5:e59-e70. [PMID: 36528541 DOI: 10.1016/s2589-7500(22)00214-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 09/22/2022] [Accepted: 11/01/2022] [Indexed: 12/23/2022]
Abstract
BACKGROUND Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is highly effective in controlling motor symptoms in patients with Parkinson's disease. However, correct selection of stimulation parameters is pivotal to treatment success and currently follows a time-consuming and demanding trial-and-error process. We aimed to assess treatment effects of stimulation parameters suggested by a recently published algorithm (StimFit) based on neuroimaging data. METHODS This double-blind, randomised, crossover, non-inferiority trial was carried out at Charité - Universitätsmedizin, Berlin, Germany, and enrolled patients with Parkinson's disease treated with directional octopolar electrodes targeted at the STN. All patients had undergone DBS programming according to our centre's standard of care (SoC) treatment before study recruitment. Based on perioperative imaging data, DBS electrodes were reconstructed and StimFit was applied to suggest optimal stimulation settings. Patients underwent motor assessments using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS-III) during OFF-medication and in OFF-stimulation and ON-stimulation states under both conditions, StimFit and SoC parameter settings. Patients were randomly assigned (1:1) to receive either StimFit-programmed DBS first and SoC-programmed DBS second, or SoC-programmed DBS first and StimFit-programmed DBS second. The allocation schedule was generated using a computerised random number generator. Both the rater and patients were masked to the sequence of SoC and StimFit stimulation conditions. All patients who participated in the study were included in the analysis. The primary endpoint of this study was the absolute mean difference between MDS-UPDRS-III scores under StimFit and SoC stimulation, with a non-inferiority margin of 5 points. The study was registered at the German Register for Clinical Trials (DRKS00023115), and is complete. FINDINGS Between July 10, 2020, and Oct 28, 2021, 35 patients were enrolled in the study; 18 received StimFit followed by SoC stimulation, and 17 received SoC followed by StimFit stimulation. Mean MDS-UPDRS-III scores improved from 47·3 (SD 17·1) at OFF-stimulation baseline to 24·7 (SD 12·4) and 26·3 (SD 12·4) under SoC and StimFit stimulation, respectively. Mean difference between motor scores was -1·6 (SD 7·1; 95% CI -4·0 to 0·9; superiority test psuperiority=0·20; n=35), establishing non-inferiority of StimFit stimulation at a margin of -5 points (non-inferiority test pnon-inferiority=0·0038). In six patients (17%), initial programming of StimFit settings resulted in acute side-effects and amplitudes were reduced until side-effects disappeared. INTERPRETATION Automated data-driven algorithms can predict stimulation parameters that lead to motor symptom control comparable to SoC treatment. This approach could significantly decrease the time necessary to obtain optimal treatment parameters. FUNDING Deutsche Forschungsgemeinschaft through NeuroCure Clinical Research Center and TRR 295.
Collapse
Affiliation(s)
- Jan Roediger
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Einstein Center for Neurosciences Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Till A Dembek
- Department of Neurology, Faculty of Medicine, University of Cologne, Cologne, Germany
| | - Johannes Achtzehn
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Johannes L Busch
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Anna-Pauline Krämer
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Katharina Faust
- Department of Neurosurgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Gerd-Helge Schneider
- Department of Neurosurgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Patricia Krause
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Andreas Horn
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Center for Brain Circuit Therapeutics, Department of Neurology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA; MGH Neurosurgery and Center for Neurotechnology and Neurorecovery (CNTR) at MGH Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Andrea A Kühn
- Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Einstein Center for Neurosciences Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; NeuroCure Clinical Research Centre, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany; DZNE, German Center for Degenerative Diseases, Berlin, Germany.
| |
Collapse
|
14
|
Feldmann LK, Lofredi R, Al-Fatly B, Busch JL, Mathiopoulou V, Roediger J, Krause P, Schneider GH, Faust K, Horn A, Kühn AA, Neumann WJ. Christmas-Related Reduction in Beta Activity in Parkinson's Disease. Mov Disord 2023; 38:692-697. [PMID: 36718788 DOI: 10.1002/mds.29334] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 12/20/2022] [Accepted: 01/09/2023] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Subthalamic nucleus (STN) beta (13 - 35 Hz) activity is a biomarker reflecting motor state in Parkinson's disease (PD). Adaptive deep brain stimulation (DBS) aims to use beta activity for therapeutic adjustments, but many aspects of beta activity in real-life situations are unknown. OBJECTIVE The aim was to investigate Christmas-related influences on beta activity in PD. METHODS Differences in Christmas Day to nonfestive daily averages in chronic biomarker recordings in 4 PD patients with a sensing-enabled STN DBS implant were retrospectively analyzed. Sweet-spot and whole-brain network connectomic analyses were performed. RESULTS Beta activity was significantly reduced on Christmas Eve in all patients (4.00-9.00 p.m.: -12.30 ± 10.78%, P = 0.015). A sweet spot in the dorsolateral STN connected recording sites to motor, premotor, and supplementary motor cortices. CONCLUSIONS We demonstrate that festive events can reduce beta biomarker activity. We conclude that circadian and holiday-related changes should be considered when tailoring adaptive DBS algorithms to patient demands. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Lucia K Feldmann
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany
| | - Roxanne Lofredi
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany
| | - Bassam Al-Fatly
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Johannes L Busch
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Varvara Mathiopoulou
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Jan Roediger
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Einstein Center for Neurosciences Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Patricia Krause
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | | | - Katharina Faust
- Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Andreas Horn
- Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.,Center for Brain Circuit Therapeutics, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Andrea A Kühn
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Berlin School of Mind and Brain, Charité University Medicine, Berlin, Germany.,NeuroCure Clinical Research Centre, Charité University Medicine, Berlin, Germany.,DZNE, German Center for Degenerative Diseases, Berlin, Germany
| | - Wolf-Julian Neumann
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Einstein Center for Neurosciences Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
15
|
Kübler D, Astalosch M, Gaus V, Krause P, de Almeida Marcelino AL, Schneider GH, Kühn A. Gender-specific outcomes of deep brain stimulation for Parkinson's disease - results from a single movement disorder center. Neurol Sci 2023; 44:1625-1631. [PMID: 36607479 PMCID: PMC10102088 DOI: 10.1007/s10072-023-06598-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Accepted: 12/31/2022] [Indexed: 01/07/2023]
Abstract
INTRODUCTION AND GOAL The investigation of gender differences in treatment response is crucial for effective personalized therapies. With only 30%, women are underrepresented in trials for deep brain stimulation (DBS) in Parkinson's disease (PD). It is therefore important to evaluate gender-specific outcomes of DBS in PD in order to improve therapeutic counseling. METHODS We analyzed clinical outcome parameters of 203 patients with PD that underwent DBS surgery targeting the subthalamic nucleus (STN) at our movement disorder center. A total of 27.6% of patients were female and 72.4% male. Motor and non-motor scores were compared before and 1 year after DBS surgery (1y FU) using Wilcoxon signed-rank tests and gender specific outcomes were analyzed with chi-square tests. RESULTS At 1y FU, we found significant improvement in UPDRS II, UPDRS III (35.78 ± 36.14% MedOFF vs. StimON-MedOFF), UPDRS IV, depression (BDI-II), and health-related disability as (ADL) that showed no gender-specific differences. No significant change was revealed for UPDRS I, QUIP, and DemTect for the entire cohort. However, when analyzing both groups separately, only women improved in general cognition (plus 1.26 ± 3.03 DemTect points, p = 0.014*), whereas only men ameliorated in depression (minus 1.97 ± 6.92 BDI-II points, p = 0.002**) and impulsivity (minus 2.80 ± 7.27 QUIP points, p = 0.004**). Chi-square tests, however, revealed no significant differences between genders. CONCLUSION AND OUTLOOK STN-DBS is a highly effective treatment for motor and non-motor symptoms of PD for both women and men but our study hints towards gender-specific outcomes in non-motor-domains like cognition, depressive symptoms, and impulsivity. To explore this in more detail, larger cohorts need to be investigated in multicenter trials.
Collapse
Affiliation(s)
- Dorothee Kübler
- Movement Disorder and Neuromodulation Unit, Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
| | - Melanie Astalosch
- Movement Disorder and Neuromodulation Unit, Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
| | - Verena Gaus
- Movement Disorder and Neuromodulation Unit, Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
- Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Patricia Krause
- Movement Disorder and Neuromodulation Unit, Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
| | - Ana Luísa de Almeida Marcelino
- Movement Disorder and Neuromodulation Unit, Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
| | - Gerd-Helge Schneider
- Department of Neurosurgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Andrea Kühn
- Movement Disorder and Neuromodulation Unit, Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
- Berlin Center for Advanced Neuroimaging, Bernstein Center for Computational Neuroscience, Berlin, Germany
- Exzellenzcluster NeuroCure, Charité - Universitätsmedizin Berlin, Berlin, Germany
- Berlin School of Mind and Brain, Humboldt - Universität Zu Berlin, Berlin, Germany
- Deutsches Zentrum Für Neurodegenerative Erkrankungen, Berlin, Germany
| |
Collapse
|
16
|
Roediger J, Dembek T, Achtzehn J, Busch J, Krämer AP, Faust K, Schneider GH, Krause P, Horn A, Kühn A. Automated deep brain stimulation programming based on electrode location – a randomized, cross-over trial using a data-driven algorithm. Brain Stimul 2023. [DOI: 10.1016/j.brs.2023.01.762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
|
17
|
Krause P, Reimer J, Kaplan J, Borngräber F, Schneider GH, Faust K, Kühn AA. Deep brain stimulation in Early Onset Parkinson's disease. Front Neurol 2022; 13:1041449. [PMID: 36468049 PMCID: PMC9713840 DOI: 10.3389/fneur.2022.1041449] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2022] [Accepted: 10/24/2022] [Indexed: 10/27/2023] Open
Abstract
INTRODUCTION Subthalamic Deep Brain Stimulation (STN-DBS) is a safe and well-established therapy for the management of motor symptoms refractory to best medical treatment in patients with Parkinson's disease (PD). Early intervention is discussed especially for Early-onset PD (EOPD) patients that present with an age of onset ≤ 45-50 years and see themselves often confronted with high psychosocial demands. METHODS We retrospectively assessed the effect of STN-DBS at 12 months follow-up (12-MFU) in 46 EOPD-patients. Effects of stimulation were evaluated by comparison of disease-specific scores for motor and non-motor symptoms including impulsiveness, apathy, mood, quality of life (QoL), cognition before surgery and in the stimulation ON-state without medication. Further, change in levodopa equivalent dosage (LEDD) after surgery, DBS parameter, lead localization, adverse and serious adverse events as well as and possible additional clinical features were assessed. RESULTS PD-associated gene mutations were found in 15% of our EOPD-cohort. At 12-MFU, mean motor scores had improved by 52.4 ± 17.6% in the STIM-ON/MED-OFF state compared to the MED-OFF state at baseline (p = 0.00; n = 42). These improvements were accompanied by a significant 59% LEDD reduction (p < 0.001), a significant 6.6 ± 16.1 points reduction of impulsivity (p = 0.02; n = 35) and a significant 30 ± 50% improvement of QoL (p = 0.01). At 12-MFU, 9 patients still worked full- and 6 part-time. Additionally documented motor and/or neuropsychiatric features decreased from n = 41 at baseline to n = 14 at 12-MFU. CONCLUSION The present study-results demonstrate that EOPD patients with and without known genetic background benefit from STN-DBS with significant improvement in motor as well as non-motor symptoms. In line with this, patients experienced a meaningful reduction of additional neuropsychiatric features. Physicians as well as patients have an utmost interest in possible predictors for the putative DBS outcome in a cohort with such a highly complex clinical profile. Longitudinal monitoring of DBS-EOPD-patients over long-term intervals with standardized comprehensive clinical assessment, accurate phenotypic characterization and documentation of clinical outcomes might help to gain insights into disease etiology, to contextualize genomic information and to identify predictors of optimal DBS candidates as well as those in danger of deterioration and/or non-response in the future.
Collapse
Affiliation(s)
- Patricia Krause
- Movement Disorder and Neuromodulation Unit, Charité University Medicine Berlin, Berlin, Germany
| | - Johanna Reimer
- Movement Disorder and Neuromodulation Unit, Charité University Medicine Berlin, Berlin, Germany
| | - Jonathan Kaplan
- Movement Disorder and Neuromodulation Unit, Charité University Medicine Berlin, Berlin, Germany
| | - Friederike Borngräber
- Movement Disorder and Neuromodulation Unit, Charité University Medicine Berlin, Berlin, Germany
| | | | - Katharina Faust
- Department of Neurosurgery, Charité University Medicine Berlin, Berlin, Germany
| | - Andrea A. Kühn
- Movement Disorder and Neuromodulation Unit, Charité University Medicine Berlin, Berlin, Germany
| |
Collapse
|
18
|
Agostini M, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Bellotti E, Belogurov S, Bettini A, Bezrukov L, Borowicz D, Bossio E, Bothe V, Brudanin V, Brugnera R, Caldwell A, Cattadori C, Chernogorov A, Comellato T, D'Andrea V, Demidova EV, Di Marco N, Doroshkevich E, Egorov V, Fischer F, Fomina M, Gangapshev A, Garfagnini A, Gooch C, Grabmayr P, Gurentsov V, Gusev K, Hakenmüller J, Hemmer S, Hiller R, Hofmann W, Hult M, Inzhechik LV, Janicskó Csáthy J, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Khushbakht H, Kihm T, Kirpichnikov IV, Klimenko A, Kneißl R, Knöpfle KT, Kochetov O, Kornoukhov VN, Krause P, Kuzminov VV, Laubenstein M, Lazzaro A, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Miloradovic M, Mingazheva R, Misiaszek M, Moseev P, Nemchenok I, Panas K, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Ransom C, Rauscher L, Riboldi S, Rumyantseva N, Sada C, Salamida F, Schönert S, Schreiner J, Schütt M, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Simgen H, Smolnikov A, Stukov D, Vasenko AA, Veresnikova A, Vignoli C, von Sturm K, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zatschler B, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. Erratum: First Search for Bosonic Superweakly Interacting Massive Particles with Masses up to 1 MeV/c^{2} with GERDA [Phys. Rev. Lett. 125, 011801 (2020)]. Phys Rev Lett 2022; 129:089901. [PMID: 36053710 DOI: 10.1103/physrevlett.129.089901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Indexed: 06/15/2023]
Abstract
This corrects the article DOI: 10.1103/PhysRevLett.125.011801.
Collapse
|
19
|
Darcy N, Lofredi R, Al-Fatly B, Neumann WJ, Hübl J, Brücke C, Krause P, Schneider GH, Kühn A. Spectral and spatial distribution of subthalamic beta peak activity in Parkinson's disease patients. Exp Neurol 2022; 356:114150. [PMID: 35732220 DOI: 10.1016/j.expneurol.2022.114150] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 05/27/2022] [Accepted: 06/15/2022] [Indexed: 11/17/2022]
Abstract
Current efforts to optimize subthalamic deep brain stimulation in Parkinson's disease patients aim to harness local oscillatory activity in the beta frequency range (13-35 Hz) as a feedback-signal for demand-based adaptive stimulation paradigms. A high prevalence of beta peak activity is prerequisite for this approach to become routine clinical practice. In a large dataset of postoperative rest recordings from 106 patients we quantified occurrence and identified determinants of spectral peaks in the alpha, low and high beta bands. At least one peak in beta band occurred in 92% of patients and 84% of hemispheres off medication, irrespective of demographic parameters, clinical subtype or motor symptom severity. Distance to previously described clinical sweet spot was significantly related both to beta peak occurrence and to spectral power (rho -0.21, p 0.006), particularly in the high beta band. Electrophysiological landscapes of our cohort's dataset in normalised space showed divergent heatmaps for alpha and beta but found similar regions for low and high beta frequency bands. We discuss potential ramifications for clinicians' programming decisions. In summary, this report provides robust evidence that spectral peaks in beta frequency range can be detected in the vast majority of Parkinsonian subthalamic nuclei, increasing confidence in the broad applicability of beta-guided deep brain stimulation.
Collapse
Affiliation(s)
- Natasha Darcy
- Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany.
| | - Roxanne Lofredi
- Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany
| | - Bassam Al-Fatly
- Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Wolf-Julian Neumann
- Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Bernstein Center for Computational Neuroscience, Humboldt-Universität, Berlin, Germany
| | - Julius Hübl
- Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Christof Brücke
- Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Patricia Krause
- Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Gerd-Helge Schneider
- Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Andrea Kühn
- Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Bernstein Center for Computational Neuroscience, Humboldt-Universität, Berlin, Germany; NeuroCure, Exzellenzcluster, Charité - Universitätsmedizin Berlin, Berlin, Germany; DZNE, German center for neurodegenerative diseases, Berlin, Germany; Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Germany
| |
Collapse
|
20
|
D'Elia C, Trenti E, Krause P, Pycha A, Mian C, Schwienbacher C, Hanspeter E, Kafka M, Palermo M, Spedicato G, Holl S, Pycha A. Xpert® bc detection as a diagnostic tool in upper urinary tract urothelial carcinoma: Preliminary results. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00374-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
21
|
Krause P, Kroneberg D, Gruber D, Koch K, Schneider GH, Kühn AA. Long-term effects of pallidal deep brain stimulation in tardive dystonia: a follow-up of 5-14 years. J Neurol 2022; 269:3563-3568. [PMID: 35083518 PMCID: PMC9217904 DOI: 10.1007/s00415-022-10965-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Revised: 01/05/2022] [Accepted: 01/06/2022] [Indexed: 11/28/2022]
Abstract
Introduction Pallidal DBS is an established treatment for severe isolated dystonia. However, its use in disabling and treatment-refractory tardive syndromes (TS) including tardive dyskinesia and tardive dystonia (TD) is less well investigated and long-term data remain sparse. This observational study evaluates long-term effects of deep brain stimulation (DBS) of the globus pallidus internus (GPi) in patients with medically refractory TS. Methods We retrospectively analyzed a cohort of seven TD patients with bilateral GPi-DBS. Involuntary movements, dystonia and disability were rated at long-term follow-up (LT-FU) after a mean of 122 ± 33.2 SD months (range 63–171 months) and compared to baseline (BL), short-term (ST-FU; mean 6 ± 2.0 SD months) and 4-year follow-up (4y-FU; mean 45 ± 12.3 SD months) using the Abnormal Involuntary Movement Scale (AIMS) and the Burke–Fahn–Marsden Dystonia Rating Scale (BFMDRS), respectively. Quality of life and mood were evaluated using the SF36 and Beck Depression Index (BDI) questionnaires, respectively. Results At LT-FU patients had improved by 73% ± 14.2 SD in involuntary movements and 90% ± 1.0 SD in dystonia. Mood had improved significantly whereas quality of life remained unchanged compared to baseline. No serious long-lasting stimulation-related adverse events (AEs) were observed. Three patients of this cohort presented without active stimulation and ongoing symptom relief at long-term follow-up after 3–10 years of continuous DBS. Conclusion Pallidal DBS is a safe and effective long-term TD treatment. Even more interesting, three of our patients could stop stimulation after several years of DBS without serious relapse. Larger studies need to explore the phenomenon of ongoing symptom relief after DBS cessation. Supplementary Information The online version contains supplementary material available at 10.1007/s00415-022-10965-8.
Collapse
Affiliation(s)
- Patricia Krause
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - Daniel Kroneberg
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - Doreen Gruber
- Department of Neurology and Stereotactic Surgery, University Medicine of Magdeburg, Magdeburg, Germany
| | - Kristin Koch
- Department of Psychiatry and Psychotherapy, Charité, University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - Gerd-Helge Schneider
- Department of Neurosurgery, Charité, University Medicine Berlin, University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - Andrea A Kühn
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany.
| |
Collapse
|
22
|
Agostini M, Araujo G, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Bellotti E, Belogurov S, Bettini A, Bezrukov L, Biancacci V, Bossio E, Bothe V, Brudanin V, Brugnera R, Caldwell A, Cattadori C, Chernogorov A, Comellato T, D’Andrea V, Demidova EV, Marco ND, Doroshkevich E, Fischer F, Fomina M, Gangapshev A, Garfagnini A, Gooch C, Grabmayr P, Gurentsov V, Gusev K, Hakenmüller J, Hemmer S, Hiller R, Hofmann W, Huang J, Hult M, Inzhechik LV, Csáthy JJ, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Khushbakht H, Kihm T, Kilgus K, Kirsch A, Kirpichnikov IV, Klimenko A, Knöpfle KT, Kochetov O, Kornoukhov VN, Krause P, Kuzminov VV, Laubenstein M, Lazzaro A, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Manzanillas L, Miloradovic M, Mingazheva R, Misiaszek M, Müller Y, Nemchenok I, Panas K, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Ransom C, Rauscher L, Redchuk M, Riboldi S, Rumyantseva N, Sada C, Salamida F, Schönert S, Schreiner J, Schütt M, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Shtembari L, Simgen H, Smolnikov A, Stukov D, Vasenko AA, Veresnikova A, Vignoli C, Sturm KV, Wagner V, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zatschler B, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. Pulse shape analysis in Gerda Phase II. Eur Phys J C Part Fields 2022; 82:284. [PMID: 35464994 PMCID: PMC8975797 DOI: 10.1140/epjc/s10052-022-10163-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 02/23/2022] [Indexed: 05/16/2023]
Abstract
The GERmanium Detector Array (Gerda) collaboration searched for neutrinoless double- β decay in 76 Ge using isotopically enriched high purity germanium detectors at the Laboratori Nazionali del Gran Sasso of INFN. After Phase I (2011-2013), the experiment benefited from several upgrades, including an additional active veto based on LAr instrumentation and a significant increase of mass by point-contact germanium detectors that improved the half-life sensitivity of Phase II (2015-2019) by an order of magnitude. At the core of the background mitigation strategy, the analysis of the time profile of individual pulses provides a powerful topological discrimination of signal-like and background-like events. Data from regular 228 Th calibrations and physics data were both considered in the evaluation of the pulse shape discrimination performance. In this work, we describe the various methods applied to the data collected in Gerda Phase II corresponding to an exposure of 103.7 kg year. These methods suppress the background by a factor of about 5 in the region of interest around Q β β = 2039 keV, while preserving ( 81 ± 3 ) % of the signal. In addition, an exhaustive list of parameters is provided which were used in the final data analysis.
Collapse
Affiliation(s)
- M. Agostini
- Department of Physics and Astronomy, University College London, London, UK
- Physik Department, Technische Universität München, Munich, Germany
| | - G. Araujo
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | | | - M. Balata
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - I. Barabanov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - L. Baudis
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - C. Bauer
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - E. Bellotti
- Dipartimento di Fisica, Università Milano Bicocca, Milan, Italy
- INFN Milano Bicocca, Milan, Italy
| | - S. Belogurov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
- NRNU MEPhI, Moscow, Russia
| | - A. Bettini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - L. Bezrukov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - V. Biancacci
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - E. Bossio
- Physik Department, Technische Universität München, Munich, Germany
| | - V. Bothe
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - V. Brudanin
- Joint Institute for Nuclear Research, Dubna, Russia
| | - R. Brugnera
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - A. Caldwell
- Max-Planck-Institut für Physik, Munich, Germany
| | | | - A. Chernogorov
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - T. Comellato
- Physik Department, Technische Universität München, Munich, Germany
| | - V. D’Andrea
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | - E. V. Demidova
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - N. Di Marco
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - E. Doroshkevich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F. Fischer
- Max-Planck-Institut für Physik, Munich, Germany
| | - M. Fomina
- Joint Institute for Nuclear Research, Dubna, Russia
| | - A. Gangapshev
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A. Garfagnini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - C. Gooch
- Max-Planck-Institut für Physik, Munich, Germany
| | - P. Grabmayr
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - V. Gurentsov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K. Gusev
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
- Physik Department, Technische Universität München, Munich, Germany
| | | | | | - R. Hiller
- Physik-Institut, Universität Zürich, Zurich, Switzerland
- Present Address: Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, Karlsruhe, Germany
| | - W. Hofmann
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - J. Huang
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - M. Hult
- European Commission, JRC-Geel, Geel, Belgium
| | - L. V. Inzhechik
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Moscow Inst. of Physics and Technology, Moscow, Russia
| | | | - J. Jochum
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - M. Junker
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - V. Kazalov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - Y. Kermaïdic
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - H. Khushbakht
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - T. Kihm
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - K. Kilgus
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - A. Kirsch
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Present Address: Robert Bosch GmbH, Stuttgart, Germany
| | - I. V. Kirpichnikov
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Klimenko
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Dubna State University, Dubna, Russia
| | - K. T. Knöpfle
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - O. Kochetov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - V. N. Kornoukhov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - P. Krause
- Physik Department, Technische Universität München, Munich, Germany
| | - V. V. Kuzminov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Laubenstein
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - A. Lazzaro
- Physik Department, Technische Universität München, Munich, Germany
| | - M. Lindner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | | | - B. Lubsandorzhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - G. Lutter
- European Commission, JRC-Geel, Geel, Belgium
| | - C. Macolino
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | | | - W. Maneschg
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | - M. Miloradovic
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - R. Mingazheva
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - M. Misiaszek
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - Y. Müller
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - I. Nemchenok
- Joint Institute for Nuclear Research, Dubna, Russia
- Present Address: Physik Department, Technische Universität München, Munich, Germany
| | - K. Panas
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - L. Pandola
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - K. Pelczar
- European Commission, JRC-Geel, Geel, Belgium
| | - L. Pertoldi
- Physik Department, Technische Universität München, Munich, Germany
- INFN Padova, Padua, Italy
| | - P. Piseri
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - A. Pullia
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - C. Ransom
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - L. Rauscher
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - M. Redchuk
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - S. Riboldi
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - N. Rumyantseva
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - C. Sada
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - F. Salamida
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | - S. Schönert
- Physik Department, Technische Universität München, Munich, Germany
| | - J. Schreiner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - M. Schütt
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A. -K. Schütz
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
- Present Address: Nuclear Science Division, Berkeley, USA
| | - O. Schulz
- Max-Planck-Institut für Physik, Munich, Germany
| | - M. Schwarz
- Physik Department, Technische Universität München, Munich, Germany
| | | | - O. Selivanenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - E. Shevchik
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | - H. Simgen
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A. Smolnikov
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - D. Stukov
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - A. A. Vasenko
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Veresnikova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C. Vignoli
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - K. von Sturm
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - V. Wagner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Present Address: Physik Department, Technische Universität München, Munich, Germany
| | - T. Wester
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - C. Wiesinger
- Physik Department, Technische Universität München, Munich, Germany
| | - M. Wojcik
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - E. Yanovich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - B. Zatschler
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - I. Zhitnikov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - S. V. Zhukov
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | | | - A. Zschocke
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | | | - K. Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - G. Zuzel
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - GERDA collaboration
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| |
Collapse
|
23
|
Krause P, Berking S, Astalosch M, Grünheid R, Kühn AA. Motor and non-motor improvements following short-term multidisciplinary day-clinic care in Parkinson´s disease. J Neural Transm (Vienna) 2022; 129:1419-1426. [PMID: 36335542 PMCID: PMC9649470 DOI: 10.1007/s00702-022-02562-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Accepted: 10/24/2022] [Indexed: 11/07/2022]
Abstract
BACKGROUND Inpatient as well as outpatient care does often not meet PD-patients' individual needs. INTRODUCTION Day-clinic concepts encompassing a multidisciplinary team as well as therapy adjustments accompanying everyday demands aim at filling this gap. METHODS This is a retrospective study on short-term effects of a 3 week multidisciplinary rehabilitation program in patients with Parkinson´s disease (PD) embedded in a specialized movement disorder day-clinic. We analyzed short-term outcome of motor and non-motor symptoms (NMS) in 143 PD-patients (mean age 65.3 ± 11.9 years; Hoehn-and-Yahr-score 2.6 ± 0.7) after 3 weeks with 7.4 ± 1.8 active days of interdisciplinary day-care treatment. Participants attended the day-clinic in groups of five patients at a time. Improvements were evaluated by comparison of standardized physical therapy assessments, disease specific scores for motor symptoms (MDS-UPDRS III), mood (BDI), quality of life (PDQ39, SF36), sleep (PDSS, ESS), impulsiveness (QUIP), apathy (SAS), cognition (MMST), as well as change in medication before and directly after the intervention. RESULTS MDS-UPDRS motor score improved significantly by 22.9 ± 21.5% (p < 0.001) and was accompanied by a significant reduction of imbalance, immobility, and weakness ranging between 6% and 17% in standardized physical therapy tests. In addition, all disease-specific non-motor scales improved significantly. CONCLUSIONS A multidisciplinary day-clinic approach can support benefit on motor, non-motor symptoms and QoL in PD-patients. Given the increase in PD incidence and prevalence as well as the significant treatment effects shown here, more day-clinic treatment opportunities ought to be implemented to improve PD treatment adapted to everyday challenges while still reducing costs to the health care system.
Collapse
Affiliation(s)
- Patricia Krause
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Charité – Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany
| | - Sara Berking
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Charité – Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany
| | - Melanie Astalosch
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Charité – Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany
| | - Raymond Grünheid
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Charité – Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany
| | - Andrea A. Kühn
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Charité – Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany
| |
Collapse
|
24
|
Krause P, Völzmann S, Ewert S, Kupsch A, Schneider GH, Kühn AA. Correction to: Long-term effects of bilateral pallidal deep brain stimulation in dystonia: a follow-up between 8 and 16 years. J Neurol 2021; 269:540. [PMID: 34779890 PMCID: PMC8739304 DOI: 10.1007/s00415-021-10863-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- P Krause
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - S Völzmann
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - S Ewert
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - A Kupsch
- Department of Neurology and Stereotactic Neurosurgery, University Medicine of Magdeburg, Magdeburg, Germany
| | - G H Schneider
- Department of Neurosurgery, Charité, University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - Andrea A Kühn
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany.
| |
Collapse
|
25
|
Li C, Krause P, Stern G. Risk factors for corticosteroid-induced hyperglycemia requiring insulin therapy in hospitalized patients without diabetes. Endocrine 2021; 73:476-479. [PMID: 33871794 DOI: 10.1007/s12020-021-02703-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Accepted: 03/17/2021] [Indexed: 01/08/2023]
Affiliation(s)
- Catherine Li
- Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Patricia Krause
- Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA
| | - Gretchen Stern
- Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
| |
Collapse
|
26
|
Barnes H, Alexander S, Bower L, Ehlers J, Gani C, Herbert T, Lawes R, Krause P, øller M, Morgan T, Nowee M, Smith G, van Triest B, Tyagi N, Whiteside L, McNair H. PD-0798 Development and results of a patient-reported treatment experience questionnaire on a 1.5 T MR-Linac. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07077-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
27
|
Agostini M, Araujo G, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Bellotti E, Belogurov S, Bettini A, Bezrukov L, Biancacci V, Bossio E, Bothe V, Brudanin V, Brugnera R, Caldwell A, Cattadori C, Chernogorov A, Comellato T, D’Andrea V, Demidova EV, Marco ND, Doroshkevich E, Fischer F, Fomina M, Gangapshev A, Garfagnini A, Gooch C, Grabmayr P, Gurentsov V, Gusev K, Hakenmüller J, Hemmer S, Hofmann W, Huang J, Hult M, Inzhechik LV, Janicskó Csáthy J, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Khushbakht H, Kihm T, Kirpichnikov IV, Klimenko A, Kneißl R, Knöpfle KT, Kochetov O, Kornoukhov VN, Krause P, Kuzminov VV, Laubenstein M, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Manzanillas L, Miloradovic M, Mingazheva R, Misiaszek M, Moseev P, Müller Y, Nemchenok I, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Ransom C, Rauscher L, Riboldi S, Rumyantseva N, Sada C, Salamida F, Schönert S, Schreiner J, Schütt M, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Shtembari L, Simgen H, Smolnikov A, Stukov D, Vasenko AA, Veresnikova A, Vignoli C, von Sturm K, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zatschler B, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. Characterization of inverted coaxial 76 Ge detectors in GERDA for future double- β decay experiments. Eur Phys J C Part Fields 2021; 81:505. [PMID: 34720720 PMCID: PMC8549949 DOI: 10.1140/epjc/s10052-021-09184-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 04/27/2021] [Indexed: 05/28/2023]
Abstract
Neutrinoless double- β decay of 76 Ge is searched for with germanium detectors where source and detector of the decay are identical. For the success of future experiments it is important to increase the mass of the detectors. We report here on the characterization and testing of five prototype detectors manufactured in inverted coaxial (IC) geometry from material enriched to 88% in 76 Ge. IC detectors combine the large mass of the traditional semi-coaxial Ge detectors with the superior resolution and pulse shape discrimination power of point contact detectors which exhibited so far much lower mass. Their performance has been found to be satisfactory both when operated in vacuum cryostat and bare in liquid argon within the Gerda setup. The measured resolutions at the Q-value for double- β decay of 76 Ge ( Q β β = 2039 keV) are about 2.1 keV full width at half maximum in vacuum cryostat. After 18 months of operation within the ultra-low background environment of the GERmanium Detector Array (Gerda) experiment and an accumulated exposure of 8.5 kg · year, the background index after analysis cuts is measured to be 4 . 9 - 3.4 + 7.3 × 10 - 4 counts / ( keV · kg · year ) around Q β β . This work confirms the feasibility of IC detectors for the next-generation experiment Legend.
Collapse
Affiliation(s)
- M. Agostini
- Department of Physics and Astronomy, University College London, London, UK
- Physik Department, Technische Universität München, Munich, Germany
| | - G. Araujo
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | | | - M. Balata
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - I. Barabanov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - L. Baudis
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - C. Bauer
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - E. Bellotti
- Dipartimento di Fisica, Università Milano Bicocca, Milan, Italy
- INFN Milano Bicocca, Milan, Italy
| | - S. Belogurov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
- NRNU MEPhI, Moscow, Russia
| | - A. Bettini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - L. Bezrukov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - V. Biancacci
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - E. Bossio
- Physik Department, Technische Universität München, Munich, Germany
| | - V. Bothe
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - V. Brudanin
- Joint Institute for Nuclear Research, Dubna, Russia
| | - R. Brugnera
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - A. Caldwell
- Max-Planck-Institut für Physik, Munich, Germany
| | | | - A. Chernogorov
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - T. Comellato
- Physik Department, Technische Universität München, Munich, Germany
| | - V. D’Andrea
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | - E. V. Demidova
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - N. Di Marco
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - E. Doroshkevich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F. Fischer
- Max-Planck-Institut für Physik, Munich, Germany
| | - M. Fomina
- Joint Institute for Nuclear Research, Dubna, Russia
| | - A. Gangapshev
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A. Garfagnini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - C. Gooch
- Max-Planck-Institut für Physik, Munich, Germany
| | - P. Grabmayr
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - V. Gurentsov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K. Gusev
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
- Physik Department, Technische Universität München, Munich, Germany
| | | | | | - W. Hofmann
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - J. Huang
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - M. Hult
- European Commission, JRC-Geel, Geel, Belgium
| | - L. V. Inzhechik
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Moscow Institute of Physics and Technology, Moscow, Russia
| | - J. Janicskó Csáthy
- Physik Department, Technische Universität München, Munich, Germany
- Leibniz-Institut für Kristallzüchtung, Berlin, Germany
| | - J. Jochum
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - M. Junker
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - V. Kazalov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - Y. Kermaïdic
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - H. Khushbakht
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - T. Kihm
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - I. V. Kirpichnikov
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Klimenko
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Dubna State University, Dubna, Russia
| | - R. Kneißl
- Max-Planck-Institut für Physik, Munich, Germany
| | - K. T. Knöpfle
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - O. Kochetov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - V. N. Kornoukhov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- NRNU MEPhI, Moscow, Russia
| | - P. Krause
- Physik Department, Technische Universität München, Munich, Germany
| | - V. V. Kuzminov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Laubenstein
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - M. Lindner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | | | - B. Lubsandorzhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - G. Lutter
- European Commission, JRC-Geel, Geel, Belgium
| | - C. Macolino
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | | | - W. Maneschg
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | - M. Miloradovic
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - R. Mingazheva
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - M. Misiaszek
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - P. Moseev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - Y. Müller
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - I. Nemchenok
- Joint Institute for Nuclear Research, Dubna, Russia
- Dubna State University, Dubna, Russia
| | - L. Pandola
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - K. Pelczar
- Institute of Physics, Jagiellonian University, Cracow, Poland
- European Commission, JRC-Geel, Geel, Belgium
| | - L. Pertoldi
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - P. Piseri
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - A. Pullia
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - C. Ransom
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - L. Rauscher
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - S. Riboldi
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - N. Rumyantseva
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - C. Sada
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - F. Salamida
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | - S. Schönert
- Physik Department, Technische Universität München, Munich, Germany
| | - J. Schreiner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - M. Schütt
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A.-K. Schütz
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - O. Schulz
- Max-Planck-Institut für Physik, Munich, Germany
| | - M. Schwarz
- Physik Department, Technische Universität München, Munich, Germany
| | | | - O. Selivanenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - E. Shevchik
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | - H. Simgen
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A. Smolnikov
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - D. Stukov
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - A. A. Vasenko
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Veresnikova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C. Vignoli
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - K. von Sturm
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - T. Wester
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - C. Wiesinger
- Physik Department, Technische Universität München, Munich, Germany
| | - M. Wojcik
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | - E. Yanovich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - B. Zatschler
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - I. Zhitnikov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - S. V. Zhukov
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | | | - A. Zschocke
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | | | - K. Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - G. Zuzel
- Institute of Physics, Jagiellonian University, Cracow, Poland
| | | |
Collapse
|
28
|
Feldmann LK, Neumann WJ, Krause P, Lofredi R, Schneider GH, Kühn AA. Subthalamic beta band suppression reflects effective neuromodulation in chronic recordings. Eur J Neurol 2021; 28:2372-2377. [PMID: 33675144 DOI: 10.1111/ene.14801] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Indexed: 01/18/2023]
Abstract
BACKGROUND AND PURPOSE Biomarkers for future adaptive deep brain stimulation still need evaluation in clinical routine. Here, we aimed to assess stimulation-induced modulation of beta-band activity and clinical symptoms in a Parkinson's disease patient during chronic neuronal sensing using a novel implantable pulse generator. METHODS Subthalamic activity was recorded OFF and ON medication during a stepwise increase of stimulation amplitude. Off-line fast fourier transfom -based analysis of beta-band activity was correlated with motor performance rated from blinded videos. RESULTS The stepwise increase of stimulation amplitude resulted in decreased beta oscillatory activity and improvement of bradykinesia. Mean low beta-band (13-20 Hz) activity correlated significantly with bradykinesia (ρ = 0.662, p < 0.01). CONCLUSIONS Motor improvement is reflected in reduced subthalamic beta-band activity in Parkinson's disease, supporting beta activity as a reliable biomarker. The novel PERCEPT neurostimulator enables chronic neuronal sensing in clinical routine. Our findings pave the way for a personalized precision-medicine approach to neurostimulation.
Collapse
Affiliation(s)
- Lucia K Feldmann
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.,Berlin Institute of Health at Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Wolf-Julian Neumann
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Patricia Krause
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Roxanne Lofredi
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Gerd-Helge Schneider
- Department of Neurosurgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Andrea A Kühn
- Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.,Berlin School of Mind and Brain, Charité University Medicine, Berlin, Germany.,NeuroCure Clinical Research Centre, Charité University Medicine, Berlin, Germany.,DZNE, German Center for Degenerative Diseases, Berlin, Germany
| |
Collapse
|
29
|
Krause P, Koch K, Gruber D, Kupsch A, Gharabaghi A, Schneider GH, Kühn AA. Long-term effects of pallidal and thalamic deep brain stimulation in myoclonus dystonia. Eur J Neurol 2021; 28:1566-1573. [PMID: 33452690 DOI: 10.1111/ene.14737] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Accepted: 01/11/2021] [Indexed: 11/27/2022]
Abstract
OBJECTIVE Observational study to evaluate long-term effects of deep brain stimulation (DBS) of the globus pallidus internus (GPi) and the ventral intermediate thalamic nucleus (VIM) on patients with medically refractory myoclonus dystonia (MD). BACKGROUND More recently, pallidal as well as thalamic DBS have been applied successfully in MD but long-term data are sparse. METHODS We retrospectively analyzed a cohort of seven MD patients with either separate (n = 1, VIM) or combined GPi- DBS and VIM-DBS (n = 6). Myoclonus, dystonia and disability were rated at baseline (BL), short-term (ST-FU) and long-term follow-up (LT-FU) using the United Myoclonus Rating Scale, Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) and Tsui rating scale, respectively. Quality of life (QoL) and mood were evaluated using the SF-36 and Beck Depression Inventory questionnaires, respectively. RESULTS Patients reached a significant reduction of myoclonus at ST-FU (62% ± 7.3%; mean ± SE) and LT-FU (68% ± 3.4%). While overall motor BFMDRS changes were not significant at LT-FU, patients with GPi-DBS alone responded better and predominant cervical dystonia ameliorated significantly up to 54% ± 9.7% at long-term. Mean disability scores significantly improved by 44% ± 11.4% at ST-FU and 58% ± 14.8% at LT-FU. Mood and QoL remained unchanged between 5 and up to 20 years postoperatively. No serious long-lasting stimulation-related adverse events were observed. CONCLUSIONS We present a cohort of MD patients with very long follow-up of pallidal and/or thalamic DBS that supports the GPi as the favourable stimulation target in MD with safe and sustaining effects on motor symptoms (myoclonus>dystonia) and disability.
Collapse
Affiliation(s)
- Patricia Krause
- Movement Disorder and Neuromodulation Unit, Charité University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - Kristin Koch
- Department of Psychiatry and Psychotherapy, Charité University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - Doreen Gruber
- Kliniken Beelitz, Movement Disorder Clinic, Beelitz-Heilstätten, Germany
| | - Andreas Kupsch
- Department of Neurology & Stereotactic Neurosurgery, University Medicine of Magdeburg, Magdeburg, Germany
| | | | - Gerd-Helge Schneider
- Department of Neurosurgery, Charité University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - Andrea A Kühn
- Movement Disorder and Neuromodulation Unit, Charité University Medicine Berlin, Campus Mitte, Berlin, Germany
| |
Collapse
|
30
|
Agostini M, Araujo G, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Bellotti E, Belogurov S, Bettini A, Bezrukov L, Biancacci V, Bossio E, Bothe V, Brudanin V, Brugnera R, Caldwell A, Cattadori C, Chernogorov A, Comellato T, D’Andrea V, Demidova EV, Marco ND, Doroshkevich E, Fischer F, Fomina M, Gangapshev A, Garfagnini A, Gooch C, Grabmayr P, Gurentsov V, Gusev K, Hakenmüller J, Hemmer S, Hiller R, Hofmann W, Huang J, Hult M, Inzhechik LV, Csáthy JJ, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Khushbakht H, Kihm T, Kirpichnikov IV, Klimenko A, Kneißl R, Knöpfle KT, Kochetov O, Kornoukhov VN, Krause P, Kuzminov VV, Laubenstein M, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Manzanillas L, Miloradovic M, Mingazheva R, Misiaszek M, Moseev P, Müller Y, Nemchenok I, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Ransom C, Rauscher L, Riboldi S, Rumyantseva N, Sada C, Salamida F, Schönert S, Schreiner J, Schütt M, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Shtembari L, Simgen H, Smolnikov A, Stukov D, Vasenko AA, Veresnikova A, Vignoli C, von Sturm K, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zatschler B, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. Calibration of the Gerda experiment. Eur Phys J C Part Fields 2021; 81:682. [PMID: 34776783 PMCID: PMC8550656 DOI: 10.1140/epjc/s10052-021-09403-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 07/01/2021] [Indexed: 05/16/2023]
Abstract
The GERmanium Detector Array (Gerda) collaboration searched for neutrinoless double- β decay in 76 Ge with an array of about 40 high-purity isotopically-enriched germanium detectors. The experimental signature of the decay is a monoenergetic signal at Q β β = 2039.061 ( 7 ) keV in the measured summed energy spectrum of the two emitted electrons. Both the energy reconstruction and resolution of the germanium detectors are crucial to separate a potential signal from various backgrounds, such as neutrino-accompanied double- β decays allowed by the Standard Model. The energy resolution and stability were determined and monitored as a function of time using data from regular 228 Th calibrations. In this work, we describe the calibration process and associated data analysis of the full Gerda dataset, tailored to preserve the excellent resolution of the individual germanium detectors when combining data over several years.
Collapse
Affiliation(s)
- M. Agostini
- Department of Physics and Astronomy, University College London, London, UK
- Physik Department, Technische Universität München, Munich, Germany
| | - G. Araujo
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | | | - M. Balata
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - I. Barabanov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - L. Baudis
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - C. Bauer
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - E. Bellotti
- Dipartimento di Fisica, Università Milano Bicocca, Milan, Italy
- INFN Milano Bicocca, Milan, Italy
| | - S. Belogurov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
- NRNU MEPhI, Moscow, Russia
| | - A. Bettini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - L. Bezrukov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - V. Biancacci
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - E. Bossio
- Physik Department, Technische Universität München, Munich, Germany
| | - V. Bothe
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - V. Brudanin
- Joint Institute for Nuclear Research, Dubna, Russia
| | - R. Brugnera
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - A. Caldwell
- Max-Planck-Institut für Physik, Munich, Germany
| | | | - A. Chernogorov
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - T. Comellato
- Physik Department, Technische Universität München, Munich, Germany
| | - V. D’Andrea
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | - E. V. Demidova
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - N. Di Marco
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - E. Doroshkevich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F. Fischer
- Max-Planck-Institut für Physik, Munich, Germany
| | - M. Fomina
- Joint Institute for Nuclear Research, Dubna, Russia
| | - A. Gangapshev
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A. Garfagnini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - C. Gooch
- Max-Planck-Institut für Physik, Munich, Germany
| | - P. Grabmayr
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - V. Gurentsov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K. Gusev
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
- Physik Department, Technische Universität München, Munich, Germany
| | | | | | - R. Hiller
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - W. Hofmann
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - J. Huang
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - M. Hult
- European Commission, JRC-Geel, Geel, Belgium
| | - L. V. Inzhechik
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Moscow Inst. of Physics and Technology, Moscow, Russia
| | - J. Janicskó Csáthy
- Physik Department, Technische Universität München, Munich, Germany
- Leibniz-Institut für Kristallzüchtung, Berlin, Germany
| | - J. Jochum
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - M. Junker
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - V. Kazalov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - Y. Kermaïdic
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - H. Khushbakht
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - T. Kihm
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - I. V. Kirpichnikov
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Klimenko
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
- Dubna State University, Dubna, Russia
| | - R. Kneißl
- Max-Planck-Institut für Physik, Munich, Germany
| | - K. T. Knöpfle
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - O. Kochetov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - V. N. Kornoukhov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - P. Krause
- Physik Department, Technische Universität München, Munich, Germany
| | - V. V. Kuzminov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Laubenstein
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - M. Lindner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | | | - B. Lubsandorzhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - G. Lutter
- European Commission, JRC-Geel, Geel, Belgium
| | - C. Macolino
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | | | - W. Maneschg
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | | | - M. Miloradovic
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - R. Mingazheva
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - M. Misiaszek
- Institute of Physics, Jagiellonian University, Kraków, Poland
| | - P. Moseev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - Y. Müller
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - I. Nemchenok
- Joint Institute for Nuclear Research, Dubna, Russia
- Dubna State University, Dubna, Russia
| | - L. Pandola
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - K. Pelczar
- Institute of Physics, Jagiellonian University, Kraków, Poland
- European Commission, JRC-Geel, Geel, Belgium
| | - L. Pertoldi
- Physik Department, Technische Universität München, Munich, Germany
- INFN Padova, Padua, Italy
| | - P. Piseri
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - A. Pullia
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - C. Ransom
- Physik-Institut, Universität Zürich, Zurich, Switzerland
| | - L. Rauscher
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - S. Riboldi
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, Milan, Italy
| | - N. Rumyantseva
- Joint Institute for Nuclear Research, Dubna, Russia
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - C. Sada
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - F. Salamida
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell’Aquila, L’Aquila, Italy
| | - S. Schönert
- Physik Department, Technische Universität München, Munich, Germany
| | - J. Schreiner
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - M. Schütt
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A-K. Schütz
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - O. Schulz
- Max-Planck-Institut für Physik, Munich, Germany
| | - M. Schwarz
- Physik Department, Technische Universität München, Munich, Germany
| | | | - O. Selivanenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - E. Shevchik
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | - H. Simgen
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - A. Smolnikov
- Joint Institute for Nuclear Research, Dubna, Russia
- Max-Planck-Institut für Kernphysik, Heidelberg, Germany
| | - D. Stukov
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | - A. A. Vasenko
- Institute for Theoretical and Experimental Physics, NRC “Kurchatov Institute”, Moscow, Russia
| | - A. Veresnikova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C. Vignoli
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, Assergi, Italy
| | - K. von Sturm
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, Padua, Italy
- INFN Padova, Padua, Italy
| | - T. Wester
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - C. Wiesinger
- Physik Department, Technische Universität München, Munich, Germany
| | - M. Wojcik
- Institute of Physics, Jagiellonian University, Kraków, Poland
| | - E. Yanovich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - B. Zatschler
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - I. Zhitnikov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - S. V. Zhukov
- National Research Centre “Kurchatov Institute”, Moscow, Russia
| | | | - A. Zschocke
- Physikalisches Institut, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | | | - K. Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden, Germany
| | - G. Zuzel
- Institute of Physics, Jagiellonian University, Kraków, Poland
| | | |
Collapse
|
31
|
Agostini M, Araujo GR, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Bellotti E, Belogurov S, Bettini A, Bezrukov L, Biancacci V, Borowicz D, Bossio E, Bothe V, Brudanin V, Brugnera R, Caldwell A, Cattadori C, Chernogorov A, Comellato T, D'Andrea V, Demidova EV, Di Marco N, Doroshkevich E, Fischer F, Fomina M, Gangapshev A, Garfagnini A, Gooch C, Grabmayr P, Gurentsov V, Gusev K, Hakenmüller J, Hemmer S, Hiller R, Hofmann W, Huang J, Hult M, Inzhechik LV, Janicskó Csáthy J, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Khushbakht H, Kihm T, Kirpichnikov IV, Klimenko A, Kneißl R, Knöpfle KT, Kochetov O, Kornoukhov VN, Krause P, Kuzminov VV, Laubenstein M, Lazzaro A, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Manzanillas L, Miloradovic M, Mingazheva R, Misiaszek M, Moseev P, Müller Y, Nemchenok I, Panas K, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Ransom C, Rauscher L, Riboldi S, Rumyantseva N, Sada C, Salamida F, Schönert S, Schreiner J, Schütt M, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Shtembari L, Simgen H, Smolnikov A, Stukov D, Vasenko AA, Veresnikova A, Vignoli C, von Sturm K, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zatschler B, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. Final Results of GERDA on the Search for Neutrinoless Double-β Decay. Phys Rev Lett 2020; 125:252502. [PMID: 33416389 DOI: 10.1103/physrevlett.125.252502] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 10/30/2020] [Accepted: 11/11/2020] [Indexed: 06/12/2023]
Abstract
The GERmanium Detector Array (GERDA) experiment searched for the lepton-number-violating neutrinoless double-β (0νββ) decay of ^{76}Ge, whose discovery would have far-reaching implications in cosmology and particle physics. By operating bare germanium diodes, enriched in ^{76}Ge, in an active liquid argon shield, GERDA achieved an unprecedently low background index of 5.2×10^{-4} counts/(keV kg yr) in the signal region and met the design goal to collect an exposure of 100 kg yr in a background-free regime. When combined with the result of Phase I, no signal is observed after 127.2 kg yr of total exposure. A limit on the half-life of 0νββ decay in ^{76}Ge is set at T_{1/2}>1.8×10^{26} yr at 90% C.L., which coincides with the sensitivity assuming no signal.
Collapse
Affiliation(s)
- M Agostini
- Department of Physics and Astronomy, University College London, London WC1E 6BT, United Kingdom
- Physik Department, Technische Universität München, 85748 Munich, Germany
| | - G R Araujo
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - A M Bakalyarov
- National Research Centre "Kurchatov Institute", 123182 Moscow, Russia
| | - M Balata
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - I Barabanov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - L Baudis
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - C Bauer
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - E Bellotti
- Dipartimento di Fisica, Università Milano Bicocca, 20126 Milan, Italy
- INFN Milano Bicocca, 20126 Milan, Italy
| | - S Belogurov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute", 117259 Moscow, Russia
| | - A Bettini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - L Bezrukov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - V Biancacci
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - D Borowicz
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - E Bossio
- Physik Department, Technische Universität München, 85748 Munich, Germany
| | - V Bothe
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - V Brudanin
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - R Brugnera
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - A Caldwell
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | | | - A Chernogorov
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute", 117259 Moscow, Russia
- National Research Centre "Kurchatov Institute", 123182 Moscow, Russia
| | - T Comellato
- Physik Department, Technische Universität München, 85748 Munich, Germany
| | - V D'Andrea
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, 67100 L'Aquila, Italy
| | - E V Demidova
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute", 117259 Moscow, Russia
| | - N Di Marco
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - E Doroshkevich
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - F Fischer
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - M Fomina
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - A Gangapshev
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Garfagnini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - C Gooch
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - P Grabmayr
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - V Gurentsov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - K Gusev
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
- National Research Centre "Kurchatov Institute", 123182 Moscow, Russia
- Physik Department, Technische Universität München, 85748 Munich, Germany
| | - J Hakenmüller
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | | | - R Hiller
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - W Hofmann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J Huang
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - M Hult
- European Commission, JRC-Geel, 2442 Geel, Belgium
| | - L V Inzhechik
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - J Janicskó Csáthy
- Physik Department, Technische Universität München, 85748 Munich, Germany
| | - J Jochum
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - M Junker
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - V Kazalov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - Y Kermaïdic
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - H Khushbakht
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - T Kihm
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - I V Kirpichnikov
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute", 117259 Moscow, Russia
| | - A Klimenko
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Kneißl
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - K T Knöpfle
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - O Kochetov
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - V N Kornoukhov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - P Krause
- Physik Department, Technische Universität München, 85748 Munich, Germany
| | - V V Kuzminov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - M Laubenstein
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - A Lazzaro
- Physik Department, Technische Universität München, 85748 Munich, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - I Lippi
- INFN Padova, 35131 Padua, Italy
| | - A Lubashevskiy
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - B Lubsandorzhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - G Lutter
- European Commission, JRC-Geel, 2442 Geel, Belgium
| | - C Macolino
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - B Majorovits
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - W Maneschg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - L Manzanillas
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - M Miloradovic
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - R Mingazheva
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - M Misiaszek
- Institute of Physics, Jagiellonian University, 31-007 Cracow, Poland
| | - P Moseev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - Y Müller
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - I Nemchenok
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - K Panas
- Institute of Physics, Jagiellonian University, 31-007 Cracow, Poland
| | - L Pandola
- INFN Laboratori Nazionali del Sud, 95123 Catania, Italy
| | - K Pelczar
- European Commission, JRC-Geel, 2442 Geel, Belgium
| | - L Pertoldi
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - P Piseri
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, 20133 Milan, Italy
| | - A Pullia
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, 20133 Milan, Italy
| | - C Ransom
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - L Rauscher
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - S Riboldi
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, 20133 Milan, Italy
| | - N Rumyantseva
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
- National Research Centre "Kurchatov Institute", 123182 Moscow, Russia
| | - C Sada
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - F Salamida
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, 67100 L'Aquila, Italy
| | - S Schönert
- Physik Department, Technische Universität München, 85748 Munich, Germany
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - M Schütt
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A-K Schütz
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - O Schulz
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - M Schwarz
- Physik Department, Technische Universität München, 85748 Munich, Germany
| | | | - O Selivanenko
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - E Shevchik
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - M Shirchenko
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - L Shtembari
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Smolnikov
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Stukov
- National Research Centre "Kurchatov Institute", 123182 Moscow, Russia
| | - A A Vasenko
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute", 117259 Moscow, Russia
| | - A Veresnikova
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - C Vignoli
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - K von Sturm
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - T Wester
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, 01069 Dresden, Germany
| | - C Wiesinger
- Physik Department, Technische Universität München, 85748 Munich, Germany
| | - M Wojcik
- Institute of Physics, Jagiellonian University, 31-007 Cracow, Poland
| | - E Yanovich
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - B Zatschler
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, 01069 Dresden, Germany
| | - I Zhitnikov
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - S V Zhukov
- National Research Centre "Kurchatov Institute", 123182 Moscow, Russia
| | - D Zinatulina
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - A Zschocke
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - A J Zsigmond
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - K Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, 01069 Dresden, Germany
| | - G Zuzel
- Institute of Physics, Jagiellonian University, 31-007 Cracow, Poland
| |
Collapse
|
32
|
Barra ME, Feske SK, Sylvester KW, Ong C, Culbreth SE, Krause P, Henderson GV, Rybak E. Fibrinogen Concentrate for the Treatment of Thrombolysis-Associated Hemorrhage in Adult Ischemic Stroke Patients. Clin Appl Thromb Hemost 2020; 26:1076029620951867. [PMID: 32946279 PMCID: PMC7502993 DOI: 10.1177/1076029620951867] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
In patients with ischemic stroke who receive systemic recombinant tissue plasminogen activator (rt-PA), the risk of secondary hemorrhage is 1-7%. Fibrinogen supplementation with cryoprecipitate is recommended in patients with rt-PA-associated symptomatic hemorrhage. We examined whether fibrinogen concentrate can be used safely in this setting. A single-center retrospective case series was performed in patients who received fibrinogen concentrate for post-rt-PA hemorrhage between January-2012 and December-2017. The primary outcome was the incidence of in-hospital thromboembolic events and infusion reactions. Secondary outcomes included incidence of clinically significant ICH expansion within 24-hours and patient serum fibrinogen response to fibrinogen concentrate therapy. Thromboembolic events occurred in 3 (12.5%) of 24 patients included in the analysis. No patients experienced infusion-related reactions. Five of 22 patients with ICH experienced clinically significant hemorrhage expansion. Hypofibrinogenemia was corrected in 87.5%(7/8) of patients with baseline hypofibrinogenemia, with a median increase in serum fibrinogen 166 mg/dL. Median fibrinogen increase in patients without baseline hypofibrinogenemia was 18 mg/dL. Fibrinogen concentrate is a safe potential therapeutic option to restore fibrinogen levels in acute ischemic stroke patients with thrombolysis-associated hemorrhage.
Collapse
Affiliation(s)
- Megan E. Barra
- Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA
- Megan E. Barra, Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.
| | - Steven K. Feske
- Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA
| | | | - Charlene Ong
- Department of Neurology, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA
| | - Sarah E. Culbreth
- Department of Pharmacy, Brigham and Women’s Hospital, Boston, MA, USA
| | - Patricia Krause
- Department of Pharmacy, Brigham and Women’s Hospital, Boston, MA, USA
| | | | - Eva Rybak
- Department of Pharmacy, Brigham and Women’s Hospital, Boston, MA, USA
| |
Collapse
|
33
|
Agostini M, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Bellotti E, Belogurov S, Bettini A, Bezrukov L, Borowicz D, Bossio E, Bothe V, Brudanin V, Brugnera R, Caldwell A, Cattadori C, Chernogorov A, Comellato T, D'Andrea V, Demidova EV, Di Marco N, Doroshkevich E, Egorov V, Fischer F, Fomina M, Gangapshev A, Garfagnini A, Gooch C, Grabmayr P, Gurentsov V, Gusev K, Hakenmüller J, Hemmer S, Hiller R, Hofmann W, Hult M, Inzhechik LV, Janicskó Csáthy J, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Khushbakht H, Kihm T, Kirpichnikov IV, Klimenko A, Kneißl R, Knöpfle KT, Kochetov O, Kornoukhov VN, Krause P, Kuzminov VV, Laubenstein M, Lazzaro A, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Miloradovic M, Mingazheva R, Misiaszek M, Moseev P, Nemchenok I, Panas K, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Ransom C, Rauscher L, Riboldi S, Rumyantseva N, Sada C, Salamida F, Schönert S, Schreiner J, Schütt M, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Simgen H, Smolnikov A, Stukov D, Vasenko AA, Veresnikova A, Vignoli C, von Sturm K, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zatschler B, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. First Search for Bosonic Superweakly Interacting Massive Particles with Masses up to 1 MeV/c^{2} with GERDA. Phys Rev Lett 2020; 125:011801. [PMID: 32678643 DOI: 10.1103/physrevlett.125.011801] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2020] [Accepted: 05/26/2020] [Indexed: 06/11/2023]
Abstract
We present the first search for bosonic superweakly interacting massive particles (super-WIMPs) as keV-scale dark matter candidates performed with the GERDA experiment. GERDA is a neutrinoless double-β decay experiment which operates high-purity germanium detectors enriched in ^{76}Ge in an ultralow background environment at the Laboratori Nazionali del Gran Sasso (LNGS) of INFN in Italy. Searches were performed for pseudoscalar and vector particles in the mass region from 60 keV/c^{2} to 1 MeV/c^{2}. No evidence for a dark matter signal was observed, and the most stringent constraints on the couplings of super-WIMPs with masses above 120 keV/c^{2} have been set. As an example, at a mass of 150 keV/c^{2} the most stringent direct limits on the dimensionless couplings of axionlike particles and dark photons to electrons of g_{ae}<3×10^{-12} and α^{'}/α<6.5×10^{-24} at 90% credible interval, respectively, were obtained.
Collapse
Affiliation(s)
- M Agostini
- Physik Department, Technische Universität München, 85748 München, Germany
| | - A M Bakalyarov
- National Research Centre "Kurchatov Institute," 123182 Moscow, Russia
| | - M Balata
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - I Barabanov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - L Baudis
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - C Bauer
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - E Bellotti
- Dipartimento di Fisica, Università Milano Bicocca, 20126 Milan, Italy
- INFN Milano Bicocca, 20126 Milan, Italy
| | - S Belogurov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute," 117259 Moscow, Russia
| | - A Bettini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - L Bezrukov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - D Borowicz
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - E Bossio
- Physik Department, Technische Universität München, 85748 München, Germany
| | - V Bothe
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - V Brudanin
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - R Brugnera
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - A Caldwell
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | | | - A Chernogorov
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute," 117259 Moscow, Russia
- National Research Centre "Kurchatov Institute," 123182 Moscow, Russia
| | - T Comellato
- Physik Department, Technische Universität München, 85748 München, Germany
| | - V D'Andrea
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, 67100 L'Aquila, Italy
| | - E V Demidova
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute," 117259 Moscow, Russia
| | - N Di Marco
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - E Doroshkevich
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - V Egorov
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - F Fischer
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - M Fomina
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - A Gangapshev
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Garfagnini
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - C Gooch
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - P Grabmayr
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - V Gurentsov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - K Gusev
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
- National Research Centre "Kurchatov Institute," 123182 Moscow, Russia
- Physik Department, Technische Universität München, 85748 München, Germany
| | - J Hakenmüller
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | | | - R Hiller
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - W Hofmann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - M Hult
- European Commission, JRC-Geel, 2440 Geel, Belgium
| | - L V Inzhechik
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - J Janicskó Csáthy
- Physik Department, Technische Universität München, 85748 München, Germany
| | - J Jochum
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - M Junker
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - V Kazalov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - Y Kermaïdic
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - H Khushbakht
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - T Kihm
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - I V Kirpichnikov
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute," 117259 Moscow, Russia
| | - A Klimenko
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Kneißl
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - K T Knöpfle
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - O Kochetov
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - V N Kornoukhov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute," 117259 Moscow, Russia
| | - P Krause
- Physik Department, Technische Universität München, 85748 München, Germany
| | - V V Kuzminov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - M Laubenstein
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - A Lazzaro
- Physik Department, Technische Universität München, 85748 München, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - I Lippi
- INFN Padova, 35131 Padua, Italy
| | - A Lubashevskiy
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - B Lubsandorzhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - G Lutter
- European Commission, JRC-Geel, 2440 Geel, Belgium
| | - C Macolino
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - B Majorovits
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - W Maneschg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - M Miloradovic
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - R Mingazheva
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - M Misiaszek
- Institute of Physics, Jagiellonian University, 31-007 Cracow, Poland
| | - P Moseev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - I Nemchenok
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - K Panas
- Institute of Physics, Jagiellonian University, 31-007 Cracow, Poland
| | - L Pandola
- INFN Laboratori Nazionali del Sud, 95123 Catania, Italy
| | - K Pelczar
- Institute of Physics, Jagiellonian University, 31-007 Cracow, Poland
| | - L Pertoldi
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - P Piseri
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, 20133 Milan, Italy
| | - A Pullia
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, 20133 Milan, Italy
| | - C Ransom
- Physik-Institut, Universität Zürich, 8057 Zurich, Switzerland
| | - L Rauscher
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - S Riboldi
- Dipartimento di Fisica, Università degli Studi di Milano and INFN Milano, 20133 Milan, Italy
| | - N Rumyantseva
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
- National Research Centre "Kurchatov Institute," 123182 Moscow, Russia
| | - C Sada
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - F Salamida
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, 67100 L'Aquila, Italy
| | - S Schönert
- Physik Department, Technische Universität München, 85748 München, Germany
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - M Schütt
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A-K Schütz
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - O Schulz
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - M Schwarz
- Physik Department, Technische Universität München, 85748 München, Germany
| | | | - O Selivanenko
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - E Shevchik
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - M Shirchenko
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Smolnikov
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Stukov
- National Research Centre "Kurchatov Institute," 123182 Moscow, Russia
| | - A A Vasenko
- Institute for Theoretical and Experimental Physics, NRC "Kurchatov Institute," 117259 Moscow, Russia
| | - A Veresnikova
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - C Vignoli
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 Assergi, Italy
| | - K von Sturm
- Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padua, Italy
- INFN Padova, 35131 Padua, Italy
| | - T Wester
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, 01069 Dresden, Germany
| | - C Wiesinger
- Physik Department, Technische Universität München, 85748 München, Germany
| | - M Wojcik
- Institute of Physics, Jagiellonian University, 31-007 Cracow, Poland
| | - E Yanovich
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - B Zatschler
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, 01069 Dresden, Germany
| | - I Zhitnikov
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - S V Zhukov
- National Research Centre "Kurchatov Institute," 123182 Moscow, Russia
| | - D Zinatulina
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - A Zschocke
- Physikalisches Institut, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany
| | - A J Zsigmond
- Max-Planck-Institut für Physik, 80805 Munich, Germany
| | - K Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, 01069 Dresden, Germany
| | - G Zuzel
- Institute of Physics, Jagiellonian University, 31-007 Cracow, Poland
| |
Collapse
|
34
|
Horn A, Wenzel G, Irmen F, Huebl J, Li N, Neumann WJ, Krause P, Bohner G, Scheel M, Kühn AA. Deep brain stimulation induced normalization of the human functional connectome in Parkinson's disease. Brain 2020; 142:3129-3143. [PMID: 31412106 DOI: 10.1093/brain/awz239] [Citation(s) in RCA: 82] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2019] [Revised: 05/12/2019] [Accepted: 06/09/2019] [Indexed: 12/20/2022] Open
Abstract
Neuroimaging has seen a paradigm shift away from a formal description of local activity patterns towards studying distributed brain networks. The recently defined framework of the 'human connectome' enables global analysis of parts of the brain and their interconnections. Deep brain stimulation (DBS) is an invasive therapy for patients with severe movement disorders aiming to retune abnormal brain network activity by local high frequency stimulation of the basal ganglia. Beyond clinical utility, DBS represents a powerful research platform to study functional connectomics and the modulation of distributed brain networks in the human brain. We acquired resting-state functional MRI in 20 patients with Parkinson's disease with subthalamic DBS switched on and off. An age-matched control cohort of 15 subjects was acquired from an open data repository. DBS lead placement in the subthalamic nucleus was localized using a state-of-the art pipeline that involved brain shift correction, multispectral image registration and use of a precise subcortical atlas. Based on a realistic 3D model of the electrode and surrounding anatomy, the amount of local impact of DBS was estimated using a finite element method approach. On a global level, average connectivity increases and decreases throughout the brain were estimated by contrasting on and off DBS scans on a voxel-wise graph comprising eight thousand nodes. Local impact of DBS on the motor subthalamic nucleus explained half the variance in global connectivity increases within the motor network (R = 0.711, P < 0.001). Moreover, local impact of DBS on the motor subthalamic nucleus could explain the degree to how much voxel-wise average brain connectivity normalized towards healthy controls (R = 0.713, P < 0.001). Finally, a network-based statistics analysis revealed that DBS attenuated specific couplings known to be pathological in Parkinson's disease. Namely, coupling between motor thalamus and motor cortex was increased while striatal coupling with cerebellum, external pallidum and subthalamic nucleus was decreased by DBS. Our results show that resting state functional MRI may be acquired in DBS on and off conditions on clinical MRI hardware and that data are useful to gain additional insight into how DBS modulates the functional connectome of the human brain. We demonstrate that effective DBS increases overall connectivity in the motor network, normalizes the network profile towards healthy controls and specifically strengthens thalamo-cortical connectivity while reducing striatal control over basal ganglia and cerebellar structures.
Collapse
Affiliation(s)
- Andreas Horn
- Department of Neurology, Movement Disorders and Neuromodulation Section, Charité - University Medicine Berlin, Berlin, Germany
| | - Gregor Wenzel
- Department of Neurology, Movement Disorders and Neuromodulation Section, Charité - University Medicine Berlin, Berlin, Germany
| | - Friederike Irmen
- Department of Neurology, Movement Disorders and Neuromodulation Section, Charité - University Medicine Berlin, Berlin, Germany.,Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany
| | - Julius Huebl
- Department of Neurology, Movement Disorders and Neuromodulation Section, Charité - University Medicine Berlin, Berlin, Germany
| | - Ningfei Li
- Department of Neurology, Movement Disorders and Neuromodulation Section, Charité - University Medicine Berlin, Berlin, Germany
| | - Wolf-Julian Neumann
- Department of Neurology, Movement Disorders and Neuromodulation Section, Charité - University Medicine Berlin, Berlin, Germany.,Department of Neuroradiology, Charité - University Medicine Berlin, Berlin, Germany
| | - Patricia Krause
- Department of Neurology, Movement Disorders and Neuromodulation Section, Charité - University Medicine Berlin, Berlin, Germany
| | - Georg Bohner
- Department of Neuroradiology, Charité - University Medicine Berlin, Berlin, Germany
| | - Michael Scheel
- Department of Neuroradiology, Charité - University Medicine Berlin, Berlin, Germany
| | - Andrea A Kühn
- Department of Neurology, Movement Disorders and Neuromodulation Section, Charité - University Medicine Berlin, Berlin, Germany.,Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany.,Exzellenzcluster NeuroCure, Charité - Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
35
|
de Almeida Marcelino AL, Horn A, Krause P, Kühn AA, Neumann WJ. Subthalamic neuromodulation improves short-term motor learning in Parkinson's disease. Brain 2020; 142:2198-2206. [PMID: 31169872 DOI: 10.1093/brain/awz152] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 03/12/2019] [Accepted: 04/08/2019] [Indexed: 11/14/2022] Open
Abstract
The basal ganglia and cerebellum are implicated in both motor learning and Parkinson's disease. Deep brain stimulation (DBS) is an established treatment for advanced Parkinson's disease that leads to motor and non-motor effects by modulating specific neural pathways. Recently, a disynaptic projection from the subthalamic nucleus (STN) to cerebellar hemispheres was discovered. To investigate the functional significance of this pathway in motor learning, short-term improvement in motor execution in 20 patients with Parkinson's disease on and off STN-DBS and 20 age-matched healthy controls was studied in a visuomotor task combined with whole-brain connectomics. Motor learning was impaired in Parkinson's disease off stimulation but was partially restored through DBS. Connectivity between active DBS contacts and a distributed network of brain regions correlated with improvement in motor learning. Region of interest analysis revealed connectivity from active contact to cerebellar hemisphere ipsilateral to hand movement as the strongest predictor for change in motor learning. Peak predictive voxels in the cerebellum localized to Crus II of lobule VII, which also showed higher STN than motor cortex connectivity, suggestive of a connection surpassing motor cortex. Our findings provide new insight into the circuit nature of Parkinson's disease and the distributed network effects of DBS in motor learning.
Collapse
Affiliation(s)
- Ana Luísa de Almeida Marcelino
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité - University Medicine Berlin, Berlin, Germany
| | - Andreas Horn
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité - University Medicine Berlin, Berlin, Germany
| | - Patricia Krause
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité - University Medicine Berlin, Berlin, Germany
| | - Andrea A Kühn
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité - University Medicine Berlin, Berlin, Germany.,Berlin School of Mind and Brain, Charité - University Medicine Berlin, Berlin, Germany.,NeuroCure, Charité - University Medicine Berlin, Berlin, Germany.,DZNE, German Centre for Degenerative Diseases, Berlin, 10117, Germany
| | - Wolf-Julian Neumann
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité - University Medicine Berlin, Berlin, Germany
| |
Collapse
|
36
|
Krause P, Völzmann S, Ewert S, Kupsch A, Schneider GH, Kühn AA. Long-term effects of bilateral pallidal deep brain stimulation in dystonia: a follow-up between 8 and 16 years. J Neurol 2020; 267:1622-1631. [PMID: 32055996 PMCID: PMC8592956 DOI: 10.1007/s00415-020-09745-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2019] [Revised: 01/31/2020] [Accepted: 02/03/2020] [Indexed: 11/29/2022]
Abstract
Objective Observational study to evaluate the long-term motor and non-motor effects of deep brain stimulation (DBS) of the globus pallidus internus (GPi) on medically refractory dystonia. Background Dystonia is a chronic disease affecting mainly young patients with a regular life expectancy and lifelong need for therapy. Pallidal DBS is an established treatment for severe isolated dystonia but long-term data are sparse. Methods We considered 36 consecutive patients with isolated generalized (n = 14) and cervical/segmental (n = 22) dystonia operated at Charité-University Hospital between 2000 and 2007 in a retrospective analysis for long-term outcome of pallidal DBS. In 19 of these patients, we could analyze dystonic symptoms and disability rated by the Burke–Fahn–Marsden Dystonia Rating scale (BFMDRS) at baseline, short-term (ST-FU, range 3–36 months) and long-term follow-up (LT-FU, range 93–197 months). Quality of life and mood were evaluated using the SF36 and Beck Depression Index (BDI) questionnaires. Results Patients reached an improvement in motor symptoms of 63.8 ± 5.7% (mean ± SE) at ST-FU and 67.9 ± 6.1% at LT-FU. Moreover, a significant and stable reduction in disability was shown following DBS (54.2 ± 9.4% at ST-FU and 53.8 ± 9.2% at LT-FU). BDI and SF36 had improved by 40% and 23%, respectively, at LT-FU (n = 14). Stimulation-induced adverse events included swallowing difficulties, dysarthria, and bradykinesia. Pulse generator (n = 3) and electrodes (n = 5) were revised in seven patients due to infection. Conclusions Pallidal DBS is a safe and efficacious long-term treatment for dystonia with sustained effects on motor impairment and disability, accompanied by a robust improvement in mood and quality of life. Electronic supplementary material The online version of this article (10.1007/s00415-020-09745-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- P Krause
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - S Völzmann
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - S Ewert
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - A Kupsch
- Department of Neurology and Stereotactic Neurosurgery, University Medicine of Magdeburg, Magdeburg, Germany
| | - G H Schneider
- Department of Neurosurgery, Charité, University Medicine Berlin, Campus Mitte, Berlin, Germany
| | - Andrea A Kühn
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany.
| |
Collapse
|
37
|
Agostini M, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Bellotti E, Belogurov S, Bettini A, Bezrukov L, Borowicz D, Brudanin V, Brugnera R, Caldwell A, Cattadori C, Chernogorov A, Comellato T, D'Andrea V, Demidova EV, Di Marco N, Domula A, Doroshkevich E, Egorov V, Falkenstein R, Fomina M, Gangapshev A, Garfagnini A, Giordano M, Grabmayr P, Gurentsov V, Gusev K, Hakenmüller J, Hegai A, Heisel M, Hemmer S, Hiller R, Hofmann W, Hult M, Inzhechik LV, Janicskó Csáthy J, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Kihm T, Kirpichnikov IV, Kirsch A, Kish A, Klimenko A, Kneißl R, Knöpfle KT, Kochetov O, Kornoukhov VN, Krause P, Kuzminov VV, Laubenstein M, Lazzaro A, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Miloradovic M, Mingazheva R, Misiaszek M, Moseev P, Nemchenok I, Panas K, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Ransom C, Riboldi S, Rumyantseva N, Sada C, Sala E, Salamida F, Schmitt C, Schneider B, Schönert S, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Simgen H, Smolnikov A, Stanco L, Stukov D, Vanhoefer L, Vasenko AA, Veresnikova A, von Sturm K, Wagner V, Wegmann A, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. Probing Majorana neutrinos with double-β decay. Science 2019; 365:1445-1448. [PMID: 31488705 DOI: 10.1126/science.aav8613] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Accepted: 08/20/2019] [Indexed: 11/02/2022]
Abstract
A discovery that neutrinos are Majorana fermions would have profound implications for particle physics and cosmology. The Majorana character of neutrinos would make possible the neutrinoless double-β (0νββ) decay, a matter-creating process without the balancing emission of antimatter. The GERDA Collaboration searches for the 0νββ decay of 76Ge by operating bare germanium detectors in an active liquid argon shield. With a total exposure of 82.4 kg⋅year, we observe no signal and derive a lower half-life limit of T 1/2 > 0.9 × 1026 years (90% C.L.). Our T 1/2 sensitivity, assuming no signal, is 1.1 × 1026 years. Combining the latter with those from other 0νββ decay searches yields a sensitivity to the effective Majorana neutrino mass of 0.07 to 0.16 electron volts.
Collapse
Affiliation(s)
- M Agostini
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - A M Bakalyarov
- National Research Centre "Kurchatov Institute," Moscow 123182, Russia
| | - M Balata
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - I Barabanov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - L Baudis
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - C Bauer
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - E Bellotti
- Dipartimento di Fisica, Università Milano Bicocca, I-20126 Milan, Italy.,INFN Milano Bicocca, I-20126 Milan, Italy
| | - S Belogurov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia.,Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - A Bettini
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - L Bezrukov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - D Borowicz
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - V Brudanin
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - R Brugnera
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - A Caldwell
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | | | - A Chernogorov
- Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - T Comellato
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - V D'Andrea
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, I-67100 L'Aquila, Italy
| | - E V Demidova
- Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - N Di Marco
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - A Domula
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, D-01069 Dresden, Germany
| | - E Doroshkevich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - V Egorov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - R Falkenstein
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - M Fomina
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - A Gangapshev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - A Garfagnini
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - M Giordano
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, I-67100 L'Aquila, Italy
| | - P Grabmayr
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - V Gurentsov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - K Gusev
- Physik Department, Technische Universität München, D-85748 Munich, Germany.,National Research Centre "Kurchatov Institute," Moscow 123182, Russia.,Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - J Hakenmüller
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - A Hegai
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - M Heisel
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - S Hemmer
- INFN Padova, I-35131 Padua, Italy
| | - R Hiller
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - W Hofmann
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - M Hult
- European Commission, JRC-Geel, B-2440 Geel, Belgium
| | - L V Inzhechik
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - J Janicskó Csáthy
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - J Jochum
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - M Junker
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - V Kazalov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - Y Kermaïdic
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - T Kihm
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - I V Kirpichnikov
- Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - A Kirsch
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - A Kish
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - A Klimenko
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany.,Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - R Kneißl
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - K T Knöpfle
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany.
| | - O Kochetov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - V N Kornoukhov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia.,Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - P Krause
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - V V Kuzminov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - M Laubenstein
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - A Lazzaro
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - I Lippi
- INFN Padova, I-35131 Padua, Italy
| | - A Lubashevskiy
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - B Lubsandorzhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - G Lutter
- European Commission, JRC-Geel, B-2440 Geel, Belgium
| | - C Macolino
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - B Majorovits
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - W Maneschg
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - M Miloradovic
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - R Mingazheva
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - M Misiaszek
- Institute of Physics, Jagiellonian University, Cracow 40-348, Poland
| | - P Moseev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - I Nemchenok
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - K Panas
- Institute of Physics, Jagiellonian University, Cracow 40-348, Poland
| | - L Pandola
- INFN Laboratori Nazionali del Sud, I-95123 Catania, Italy
| | - K Pelczar
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - L Pertoldi
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - P Piseri
- Dipartimento di Fisica, Università degli Studi di Milano e INFN Milano, I-20133 Milan, Italy
| | - A Pullia
- Dipartimento di Fisica, Università degli Studi di Milano e INFN Milano, I-20133 Milan, Italy
| | - C Ransom
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - S Riboldi
- Dipartimento di Fisica, Università degli Studi di Milano e INFN Milano, I-20133 Milan, Italy
| | - N Rumyantseva
- National Research Centre "Kurchatov Institute," Moscow 123182, Russia.,Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - C Sada
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - E Sala
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - F Salamida
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, I-67100 L'Aquila, Italy
| | - C Schmitt
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - B Schneider
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, D-01069 Dresden, Germany
| | - S Schönert
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - A-K Schütz
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - O Schulz
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - M Schwarz
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | | | - O Selivanenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - E Shevchik
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - M Shirchenko
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - H Simgen
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - A Smolnikov
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany.,Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - L Stanco
- INFN Padova, I-35131 Padua, Italy
| | - D Stukov
- National Research Centre "Kurchatov Institute," Moscow 123182, Russia
| | - L Vanhoefer
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - A A Vasenko
- Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - A Veresnikova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - K von Sturm
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - V Wagner
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - A Wegmann
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - T Wester
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, D-01069 Dresden, Germany
| | - C Wiesinger
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - M Wojcik
- Institute of Physics, Jagiellonian University, Cracow 40-348, Poland
| | - E Yanovich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - I Zhitnikov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - S V Zhukov
- National Research Centre "Kurchatov Institute," Moscow 123182, Russia
| | - D Zinatulina
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - A Zschocke
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - A J Zsigmond
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - K Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, D-01069 Dresden, Germany
| | - G Zuzel
- Institute of Physics, Jagiellonian University, Cracow 40-348, Poland
| | | |
Collapse
|
38
|
Scheller U, Lofredi R, Wijk BC, Saryyeva A, Krauss JK, Schneider G, Kroneberg D, Krause P, Neumann W, Kühn AA. Pallidal low‐frequency activity in dystonia after cessation of long‐term deep brain stimulation. Mov Disord 2019; 34:1734-1739. [DOI: 10.1002/mds.27838] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Revised: 08/05/2019] [Accepted: 08/05/2019] [Indexed: 01/05/2023] Open
Affiliation(s)
- Ute Scheller
- Charité, Universitätsmedizin Berlin Campus Mitte, Movement Disorders and Neuromodulation Unit, Department of Neurology Berlin Germany
| | - Roxanne Lofredi
- Charité, Universitätsmedizin Berlin Campus Mitte, Movement Disorders and Neuromodulation Unit, Department of Neurology Berlin Germany
| | - Bernadette C.M. Wijk
- Charité, Universitätsmedizin Berlin Campus Mitte, Movement Disorders and Neuromodulation Unit, Department of Neurology Berlin Germany
- Integrative Model‐Based Cognitive Neuroscience Research Unit, Department of Psychology University of Amsterdam Amsterdam the Netherlands
- Wellcome Centre for Human Neuroimaging University College London Institute of Neurology London UK
| | - Assel Saryyeva
- Medizinische Hochschule Hannover Department of Neurosurgery Hannover Germany
| | - Joachim K. Krauss
- Medizinische Hochschule Hannover Department of Neurosurgery Hannover Germany
| | - Gerd‐Helge Schneider
- Charité, Universitätsmedizin Berlin Campus Mitte, Department of Neurosurgery Berlin Germany
| | - Daniel Kroneberg
- Charité, Universitätsmedizin Berlin Campus Mitte, Movement Disorders and Neuromodulation Unit, Department of Neurology Berlin Germany
| | - Patricia Krause
- Charité, Universitätsmedizin Berlin Campus Mitte, Movement Disorders and Neuromodulation Unit, Department of Neurology Berlin Germany
| | - Wolf‐Julian Neumann
- Charité, Universitätsmedizin Berlin Campus Mitte, Movement Disorders and Neuromodulation Unit, Department of Neurology Berlin Germany
| | - Andrea A. Kühn
- Charité, Universitätsmedizin Berlin Campus Mitte, Movement Disorders and Neuromodulation Unit, Department of Neurology Berlin Germany
- NeuroCure Universitätsmedizin Berlin Berlin Germany
| |
Collapse
|
39
|
Koy A, Bockhorn N, Kühn A, Schneider GH, Krause P, Lauritsch K, Witt K, Paschen S, Deuschl G, Krauss J, Saryyeva A, Runge J, Borggraefe I, Mehrkens J, Horn A, Vesper J, Schnitzler A, Siegert S, Freilinger M, Eckenweiler M, Coenen V, Tadic V, Voges J, Pauls K, Wirths J, Timmermann L, Hellmich M, Abdallat M, Ascencao LC, Grünwald S, Wloch A, Schrader C, Groiss SJ, Wojtecki L. Adverse events associated with deep brain stimulation in patients with childhood-onset dystonia. Brain Stimul 2019; 12:1111-1120. [DOI: 10.1016/j.brs.2019.04.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 03/15/2019] [Accepted: 04/02/2019] [Indexed: 11/29/2022] Open
|
40
|
Gruber D, Calmbach L, Kühn AA, Krause P, Kopp UA, Schneider GH, Kupsch A. Longterm outcome of cognition, affective state, and quality of life following subthalamic deep brain stimulation in Parkinson’s disease. J Neural Transm (Vienna) 2019; 126:309-318. [DOI: 10.1007/s00702-019-01972-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2018] [Accepted: 01/11/2019] [Indexed: 11/29/2022]
|
41
|
Neumann WJ, Schroll H, de Almeida Marcelino AL, Horn A, Ewert S, Irmen F, Krause P, Schneider GH, Hamker F, Kühn AA. Functional segregation of basal ganglia pathways in Parkinson’s disease. Brain 2018; 141:2655-2669. [DOI: 10.1093/brain/awy206] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Accepted: 06/19/2018] [Indexed: 01/09/2023] Open
Affiliation(s)
- Wolf-Julian Neumann
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Henning Schroll
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Ana Luisa de Almeida Marcelino
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Andreas Horn
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Siobhan Ewert
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Friederike Irmen
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Department of Biological Psychology and Cognitive Neuroscience, Freie Universität Berlin, Germany
- Berlin School of Mind and Brain, Humboldt-Universitaet zu Berlin, Germany
| | - Patricia Krause
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Gerd-Helge Schneider
- Department of Neurosurgery, Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - Fred Hamker
- Department of Computer Science, Chemnitz University of Technology, Chemnitz, Germany
| | - Andrea A Kühn
- Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Neurocure, Centre of Excellence, Charité – Universitätsmedizin Berlin, Berlin, Germany
- DZNE, German Center for Degenerative Diseases, Berlin, Germany
| |
Collapse
|
42
|
Boyaciyan D, Krause P, von Klitzing R. Making strong polyelectrolyte brushes pH-sensitive by incorporation of gold nanoparticles. Soft Matter 2018; 14:4029-4039. [PMID: 29670976 DOI: 10.1039/c8sm00411k] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Doping polymer brushes with gold nanoparticles (AuNPs) results in composite materials with colorimetric sensor properties. The present paper addresses the effect of electrostatic particle-particle interaction and the effect of the polymer brush type on particle assembly formation within the polymer matrix. The prospect for long-term use as colorimetric sensors is tested. Therefore, two different types of brushes of pH-insensitive polymers, non-ionic poly(N-isopropylacrylamide) (PNIPAM) and cationic poly-[2-(methacryloyloxy)ethyl] trimethylammonium chloride (PMETAC), are studied. After incubation of the non-ionic PNIPAM brush in an aqueous suspension of AuNPs with a pH-sensitive carboxylic acid capping, hydrogen binding led to attachment of the AuNPs, but they were easily detached at high pH due to loss of the hydrogen binding. In contrast, the anionic AuNPs adhere well to cationic PMETAC brushes even after post-treatment at low pH where the charge density of the AuNPs is strongly reduced. Therefore, the PMETAC/AuNP composites were further tested with respect to their stability against pH variations and their impact for colorimetric sensors. Although the neat PMETAC brush is not pH-sensitive, after embedding pH-sensitive AuNPs, the PMETAC/AuNP composite becomes pH-sensitive in a reversible manner. This is detectable by the reversible shift of the plasmon band and the reversible thickness change of the composites by exposing them to different pH.
Collapse
Affiliation(s)
- D Boyaciyan
- Soft Matter at Interfaces, Technische Universität Darmstadt, Alarich-Weiss-Straße 10, 64287 Darmstadt, Germany.
| | | | | |
Collapse
|
43
|
Bork H, Simmel S, Böhle E, Ernst U, Fischer K, Fromm B, Glaesener JJ, Greitemann B, Krause P, Panning S, Pullwitt V, Schmidt J, Veihelmann A, Vogt L. [Rehabilitation after Traumatic Fracture of Thoracic and Lumbar Spine]. Z Orthop Unfall 2018; 156:533-540. [PMID: 29775977 DOI: 10.1055/a-0591-6712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
On the basis of the S2-k guideline "Rehabilitation after traumatic fractures of the thoracic und lumbar spine without neurologic disorder", this article gives an overview of target-oriented rehabilitation of patients with minor fractures or those with column stability and unstable spinal fractures which are stabilised by surgery. To obtain early social and job related reintegration, outpatient or inpatient rehabilitation has to start immediately after treatment in hospital. Rehabilitation must be orientated towards the biopsychosocial model of ICF and has to be adapted for the patient. The overall goal of rehabilitation is functional restoration of patient health to enable participation in society, life and job. Individual goals may change during rehabilitation, because of differential progress in therapy. Pain management must be orientated towards individual requirements and mental health has to be tested early, especially in polytrauma patients. Disorders have to be treated by psychotherapy, because psychic stress supports chronification of pain. Generally early exercise and physiotherapy are recommended in the guideline, with patient education for health-seeking behavior. Otherwise an orthesis device is not really necessary for treatment of a stable fracture. To improve the outcome of rehabilitation aftercare, treatment has to be arranged during rehabilitation, especially for employed patients.
Collapse
Affiliation(s)
- Hartmut Bork
- Reha-Zentrum am St. Josef-Stift, St. Josef-Stift Sendenhorst
| | | | | | | | - Klaus Fischer
- Klinik für Physikalische und Rehabilitative Medizin, BG Klinikum Bergmannstrost Halle
| | - Bernd Fromm
- REHA-Klinik Sigmund Weil GmbH, Bad Schönborn
| | | | | | - P Krause
- Deutscher Verband der Ergotherapeuten e. V., Karlsbad-Ittersbach
| | | | - V Pullwitt
- Deutscher Verband der Ergotherapeuten e. V., Karlsbad-Ittersbach
| | - J Schmidt
- Reha Assist Deutschland GmbH, Arnsberg
| | | | - Lutz Vogt
- Institut für Sportwissenschaften, Abteilung Sportmedizin, Goethe-Universität Frankfurt
| |
Collapse
|
44
|
de Lusignan S, Krause P, Michalakidis G, Vicente M, Thompson S, McGilchrist M, Sullivan F, van Royen P, Agreus L, Desombre T, Taweel A, Delaney B. Business Process Modelling is an Essential Part of a Requirements Analysis. Yearb Med Inform 2018. [DOI: 10.1055/s-0038-1639428] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
SummaryTo perform a requirements analysis of the barriers to conducting research linking of primary care, genetic and cancer data.We extended our initial data-centric approach to include socio-culturalandbusinessrequirements.Wecreatedreferencemodels of core data requirements common to most studies using unified modelling language (UML), dataflow diagrams (DFD) and business process modelling notation (BPMN). We conducted a stakeholder analysis and constructed DFD and UML diagrams for use cases based on simulated research studies. We used research output as a sensitivity analysis.Differences between the reference model and use cases identified study specific data requirements. The stakeholder analysis identified: tensions, changes in specification, some indifference from data providers and enthusiastic informaticians urging inclusion of socio-cultural context. We identified requirements to collect information at three levels: microdata items, which need to be semantically interoperable, meso-the medical record and data extraction, and macro-the health system and socio-cultural issues. BPMN clarified complex business requirements among data providers and vendors; and additional geographical requirements for patients to be represented in both linked datasets. High quality research output was the norm for most repositories.Reference models provide high-level schemata of the core data requirements. However, business requirements’ modelling identifies stakeholder issues and identifies what needs to be addressed to enable participation.
Collapse
|
45
|
de Lusignan S, Liaw ST, Krause P, Curcin V, Vicente M, Michalakidis G, Agreus L, Leysen P, Shaw N, Mendis K. Key Concepts to Assess the Readiness of Data for International Research: Data Quality, Lineage and Provenance, Extraction and Processing Errors, Traceability, and Curation. Yearb Med Inform 2018. [DOI: 10.1055/s-0038-1638748] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
SummaryTo define the key concepts which inform whether a system for collecting, aggregating and processing routine clinical data for research is fit for purpose.Literature review and shared experiential learning from research using routinely collected data. We excluded socio-cultural issues, and privacy and security issues as our focus was to explore linking clinical data.Six key concepts describe data: (1) Data quality: the core Overarching concept – Are these data fit for purpose? (2) Data provenance: defined as how data came to be; incorporating the concepts of lineage and pedigree. Mapping this process requires metadata. New variables derived during data analysis have their own provenance. (3) Data extraction errors and (4) Data processing errors, which are the responsibility of the investigator extracting the data but need quantifying. (5) Traceability: the capability to identify the origins of any data cell within the final analysis table essential for good governance, and almost impossible without a formal system of metadata; and (6) Curation: storing data and look-up tables in a way that allows future researchers to carry out further research or review earlier findings.There are common distinct steps in processing data; the quality of any metadata may be predictive of the quality of the process. Outputs based on routine data should include a review of the process from data origin to curation and publish information about their data provenance and processing method.
Collapse
|
46
|
Abstract
Transplantation of isolated hepatocytes is a promising alternative to orthotopic liver transplantation in experimental animal models with acute hepatic failure and hereditary enzyme defects. Conventional light microscopy identification of hepatocytes within recipient livers has been limited due to the inability to distinguish between donor and recipient liver cells. In this study, we labeled hepatocytes intracellularly with the fluorescent dye DiI-18 prior to selective intraportal or intrasplenic transplantation. Syngeneic LEW rat hepatocytes were isolated and 2 × 107 fluorescence-labeled cells were transplanted by intraportal infusion selectively into 2/3 of the recipient liver lobules to avoid lethal portal hypertension. Rats were sacrificed on postop days 1, 3, 5, 10, 20, and 40. Histological examination was performed using light and fluorescence microscopy counterstained by light green dye. The quantity of transplanted hepatocytes residing within the recipient liver was determined by FACS analysis after enzymatic digestion of the recipient liver lobules. Engrafted hepatocytes were identified in the periportal regions of transplanted liver lobules. The stained hepatocytes were retrieved up to 20 days postop using fluorescent microscopy. Using FACS analysis the number of labeled hepatocytes was found to diminish over time following transplantation from 2.1% on postop day 1 to 0.5% on day 10. Labeled hepatocytes transplanted into the spleen were retrieved in clusters up to 20 days postop (the last day of observation). Furthermore, the migration of labeled hepatocytes from spleen to liver parenchyma was observed following intrasplenic transplantation. However, after selective intraportal transplantation, only fluorescent debris was found in splenic and pulmonary tissue upon examination of various organs. This article describes the method of fluorescent labeling of rat hepatocytes and reports the feasibility and limitations of using DiI-18 as a marker.
Collapse
Affiliation(s)
- P M Markus
- Department of General Surgery, Georg August University of Göttingen, Germany
| | | | | | | |
Collapse
|
47
|
Abstract
Hepatocyte transplantation is an intriguing alternative to orthotopic liver transplantation. While engraftment of syngeneic hepatocytes can be achieved with relative ease, engraftment of allogeneic hepatocytes has been far more complicated. We used FK 506 (Tacrolimus), a novel and highly efficient immunosuppressant, which has been reported to augment liver regeneration in rats. Recipients of isolated syngeneic (LEW) and allogeneic (Wistar F.) rat hepatocytes (major histocompatibility barrier) recieved different immunosuppressive regiments with FK 506 or Cyclosporine A (CsA). Mature syngeneic hepatocytes could be retrieved up to post op day 300 with the lowest number of hepatocytes on post op day 20. Following allogeneic transplantation, no mature hepatocytes could be identified after post op day 10, though ductular like structures within the spleen were found in FK 506 but not CsA-treated animals. The epithelial cells of ductular like structures exhibit cytological features of CK-19 positive cells. Our results suggest that under CsA or FK 506 immunosuppression long-term survival of mature allogeneic hepatocytes within the spleen cannot be achieved across a major histocompatibility barrier though FK 506 allows engraftment of allogeneic donor type ductular cells. Copyright © 1997 Elsevier Science Inc.
Collapse
Affiliation(s)
- P M Markus
- Department of General Surgery and Pathology, Georg August University of Göttingen, Germany
| | | | | | | | | |
Collapse
|
48
|
Abstract
When people with epilepsy are hospitalised for medical or surgical conditions, they may be unable to take their home antiepileptic drugs (AEDs). Such 'nil by mouth' people with epilepsy require alternative AED regimens to prevent breakthrough seizures. Here, we describe several strategies for maintaining seizure control in patients with epilepsy who have medical or surgical contraindications to their home oral regimens. These strategies include using non-pill oral formulations, using an intravenous formulation of the patient's home AED(s), using a benzodiazepine bridge and/or using alternative intravenous AED(s) when there are no intravenous formulations.
Collapse
Affiliation(s)
- Anna M Bank
- Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Jong Woo Lee
- Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Patricia Krause
- Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Aaron L Berkowitz
- Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| |
Collapse
|
49
|
Koy A, Weinsheimer M, Pauls KAM, Kühn AA, Krause P, Huebl J, Schneider GH, Deuschl G, Erasmi R, Falk D, Krauss JK, Lütjens G, Schnitzler A, Wojtecki L, Vesper J, Korinthenberg R, Coenen VA, Visser-Vandewalle V, Hellmich M, Timmermann L. German registry of paediatric deep brain stimulation in patients with childhood-onset dystonia (GEPESTIM). Eur J Paediatr Neurol 2017; 21:136-146. [PMID: 27424797 DOI: 10.1016/j.ejpn.2016.05.023] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2016] [Accepted: 05/22/2016] [Indexed: 11/16/2022]
Abstract
BACKGROUND Data on paediatric deep brain stimulation (DBS) is limited, especially for long-term outcomes, because of small numbers in single center series and lack of systematic multi-center trials. OBJECTIVES We seek to systematically evaluate the clinical outcome of paediatric patients undergoing DBS. METHODS A German registry on paediatric DBS (GEPESTIM) was created to collect data of patients with dystonia undergoing DBS up to the age of 18 years. Patients were divided into three groups according to etiology (group 1 inherited, group 2 acquired, and group 3 idiopathic dystonia). RESULTS Data of 44 patients with a mean age of 12.8 years at time of operation provided by 6 German centers could be documented in the registry so far (group 1 n = 18, group 2 n = 16, group 3 n = 10). Average absolute improvement after implantation was 15.5 ± 18.0 for 27 patients with pre- and postoperative Burke-Fahn-Marsden Dystonia Rating scale movement scores available (p < 0.001) (group 1: 19.6 ± 19.7, n = 12; group 2: 7.0 ± 8.9, n = 8; group 3: 19.2 ± 20.7, n = 7). Infection was the main reason for hardware removal (n = 6). 20 IPG replacements due to battery expiry were necessary in 15 patients at 3.7 ± 1.8 years after last implantation. DISCUSSION Pre- and postoperative data on paediatric DBS are very heterogeneous and incomplete but corroborate the positive effects of DBS on inherited and acquired dystonia. Adverse events including relatively frequent IPG replacements due to battery expiry seem to be a prominent feature of children with dystonia undergoing DBS. The registry enables collaborative research on DBS treatment in the paediatric population and to create standardized management algorithms in the future.
Collapse
Affiliation(s)
- A Koy
- Department of Neurology, University Hospital of Cologne, Germany; Department of Paediatrics, University Hospital of Cologne, Germany.
| | - M Weinsheimer
- Department of Neurology, University Hospital of Cologne, Germany
| | - K A M Pauls
- Department of Neurology, University Hospital of Cologne, Germany
| | - A A Kühn
- Department of Neurology, Charité University Medicine Berlin, Germany
| | - P Krause
- Department of Neurology, Charité University Medicine Berlin, Germany
| | - J Huebl
- Department of Neurology, Charité University Medicine Berlin, Germany
| | - G-H Schneider
- Department of Neurosurgery, Charité University Medicine Berlin, Germany
| | - G Deuschl
- Department of Neurology, University Hospital of Schleswig-Holstein, Campus Kiel, Germany
| | - R Erasmi
- Department of Neurology, University Hospital of Schleswig-Holstein, Campus Kiel, Germany
| | - D Falk
- Department of Neurosurgery, University Hospital of Schleswig-Holstein, Campus Kiel, Germany
| | - J K Krauss
- Department of Neurosurgery, Medical School, MHH, Hannover, Germany
| | - G Lütjens
- Department of Neurosurgery, Medical School, MHH, Hannover, Germany
| | - A Schnitzler
- Department of Neurology, University Hospital of Düsseldorf, Germany
| | - L Wojtecki
- Department of Neurology, University Hospital of Düsseldorf, Germany
| | - J Vesper
- Department of Stereotactic and Functional Neurosurgery, University Hospital of Düsseldorf, Germany
| | - R Korinthenberg
- Department of Paediatrics, Freiburg University Medical Centre, Germany
| | - V A Coenen
- Department Stereotactic and Functional Neurosurgery, Freiburg University Medical Centre, Germany
| | - V Visser-Vandewalle
- Department of Stereotactic and Functional Neurosurgery, University Hospital of Cologne, Germany
| | - M Hellmich
- Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Germany
| | - L Timmermann
- Department of Neurology, University Hospital of Cologne, Germany.
| | | |
Collapse
|
50
|
Kesal D, Christau S, Trapp M, Krause P, von Klitzing R. The internal structure of PMETAC brush/gold nanoparticle composites: a neutron and X-ray reflectivity study. Phys Chem Chem Phys 2017; 19:30636-30646. [DOI: 10.1039/c7cp04404f] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The amount and distribution of gold nanoparticles within a polymer brush matrix can be changed by altering the electrostatic interaction between particle–particle as well as particle–brush.
Collapse
Affiliation(s)
- D. Kesal
- Soft Matter at Interfaces
- Technische Universität Darmstadt
- 64287 Darmstadt
- Germany
| | - S. Christau
- Department of Chemical Engineering
- University of Michigan
- Ann Arbor
- USA
| | - M. Trapp
- Helmholtz-Zentrum Berlin für Materialien und Energie
- 14109 Berlin
- Germany
| | - P. Krause
- Stranski-Laboratorium für Phyisikalische Chemie
- Technische Universität Berlin
- 10623 Berlin
- Germany
| | - R. von Klitzing
- Soft Matter at Interfaces
- Technische Universität Darmstadt
- 64287 Darmstadt
- Germany
| |
Collapse
|